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from the editors. . .
Medical students attending The George
Washington University School of Medicine and
Health Sciences routinely engage in biomedical
research of a high quality. We are proud to
present a diverse sampling of these research
efforts with this publication, authored by our
fellow medical students for presentation to The
George Washington University Medical Center
(GWUMC) community. The articles in the following pages span several disciplines, including
basic science “bench” research, clinical “bedside”
efforts, endeavors in global and public health,
and medical education. From elaborate studies
of leukemic cells, to new technologies in spinal
surgery, to health travel experiences in rural
India, GW medical students continue to impress
in both the depth and scope of their work.
Putting together this journal was both
rewarding and challenging. Members of the student editorial board, composed of officers of the
William H. Beaumont Medical Research Honor
Society, solicited submissions from the medical
school Classes of 2010 and 2011. We received a
strong response. The editors and editorial board,
along with selected faculty, collectively and rigorously reviewed each submission. Responsibility
for the content of the articles, however, remains
with the respective author(s). In this second
edition of Fusion, we are pleased to publish 31
submissions, reflecting an extraordinary range of
our peers’ research experiences.
The Dean’s Office and Office of Student
Opportunities continually offer superb guidance
to medical students interested in undertaking
research, and both deserve special recognition.
In particular, both offices jointly fostered the
creation of track programs in research, global
health, health policy, and medical education,
among others, to focus student interest and
generate connections with experienced and talented faculty—at GWUMC and throughout the
country. The diversity and quality of research in
Fusion is a testament to their vision.

Fusion • 2008

We thank James Scott, MD, FACEP, and
W. Scott Schroth, MD, MPH, in the Office of
the Dean; Anne Hirshfield, PhD, our faculty
advisor in the Office of Research; Linda Dent
and Debbie Goldstein in Medical Center of
Communications and Marketing; as well as the
numerous GWUMC faculty members who took
time from their hectic schedules to review submissions. We also thank the editors of last year’s
debut edition of Fusion: Andrew Lerner, Vivek
Patil and Rahul Arya. Their ingenuity, hard
work and guidance helped lay the foundation
for the journal you read today. Finally, we especially thank Thomas Kohout, in the Office of
Communications and Marketing, for serving as
our wonderful managing editor, and our editorial
board for their diligence and hard work.
Medical research is an incredibly exciting
endeavor, paving the way for important breakthroughs that expand our knowledge of the
human body and enhance all dimensions of
patient care. We hope the second annual edition
of Fusion conveys this excitement to you.

Andrew H. Gordon, PhD, MSII

Steven V. Kardos, MSII

Warm regards,

Ajay Wadgaonkar, MSII
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from the dean’s office. . .
While it is indisputable that
medicine is based on the
foundations of science, how
we define that science is anything but narrow in scope and
quality. Laboratory research,
clinical studies, communitybased projects and outreach
across the globe all qualify
as scientific endeavors, if the
results of these activities are
scrutinized in an organized
way, discussed openly and form
the beginnings of ongoing
inquiry. The first step in that
process is to publish something
based on the work and begin a
dialogue about its importance,
relevance and future directions. In this second
edition of Fusion, students from The George
Washington University School of Medicine
and Health Sciences (SMHS) have gathered an
impressive collection of contributions that span
the experiences of scientific endeavors for SMHS
students. I can say that I’m not only delighted
to read about the activities of our students, but
also extremely proud of their many and diverse
accomplishments.
This journal was conceived by medical
students in the William H. Beaumont Medical
Research Honor Society and I commend them
for their work. Specifically, I want to recognize
Steven Kardos, Ajay Wadgaonkar and Andrew
Gordon for their creativity and thoroughness in
gathering, editing and organizing these projects.
This journal would not exist without their hard
work and vision. I also want to thank Associate
Vice President Anne Hirshfield, PhD, for her
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guidance and mentorship of the Beaumont
Society and her encouragement of the students
working on this journal. We are also indebted
to the Office of Student Opportunities which
arranged many of these projects for the students,
and the generous individual supporters in that
office, specifically Dr. and Mrs. Gerald Lazarus,
Dr. Christopher Barley, Dr. Keshav Narain,
Dr. Charles Walkoff and Dr. Robert Rosenberg.
In addition, none of this would have been possible without the active involvement of so many
of our faculty in the research and other activities
of our medical students. To all of you, a collective thank you.
I encourage you to take your time as you
journey through these pages getting a glimpse
of the variety of activities that are available to
students at The George Washington University
School of Medicine and Health Sciences. There
is no doubt that this school has a unique geographic location which creates extraordinary
opportunities for students to participate in ways
that are much more difficult at other institutions.
It is also true that, with those opportunities,
comes a responsibility to discuss our discoveries
in science, policy and health outreach in an open
and critical way and to make our findings accessible to a larger audience. This journal, thanks to
all those who contributed, is a great beginning.
My congratulations to you all.

James L. Scott, MD
Dean, School of Medicine and Health Sciences,
Professor of Emergency Medicine
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from the research office. . .
It is with great pleasure that I invite readers to
explore the 2008 edition of Fusion, the second
volume of a publication that was conceived
and implemented by officers of The George
Washington University’s Beaumont Society. The
William H. Beaumont Medical Research Honor
Society was established at the GW School of
Medicine in 1935 to promote student research.
Although I have the honor of serving as this
group’s faculty advisor, the Society is entirely
student run.
Fusion came into being because Beaumont
Society officers wanted a vehicle for capturing
and preserving the variety of experiences students
had while carrying out research rotations and
summer research projects, activities that many of
our students undertake during their pre-clinical
years. The officers wanted to communicate the
excitement and value of these experiences to
a wider audience. Last year’s first edition was
received with great enthusiasm and, as a result,
members of the Society have decided that the
publication should become an annual tradition.
This project is entirely student driven, and
therefore a real testament to the students themselves who devoted a tremendous amount of
time and effort to its production. Considering
the demands of their medical education, this
publication represents an outstanding achievement for those involved. In acknowledging all
those who made this second volume of Fusion
a reality, thanks go to the Office of Medical
Center Communications and Marketing, who
contributed their expertise in assuring the
professional appearance of this publication.
Acknowledgements and thanks are also due
to the faculty research advisors who welcomed
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the student researchers into
their programs and mentored
their research activities and
progress. Finally, we need to
recognize contribution of the
W.T. Gill Endowment, which
provided summer stipends for
most of the students whose
work is described in this
journal. Our gratitude for this
invaluable resource cannot be
overstated.
Many of the students
whose work appears on these
pages are among the best and
most enthusiastic in their
class. Some will undoubtedly
go on to careers in research,
joining the ranks of our many GW alumni who
have made major contributions to collective
knowledge about improving the health and well
being of humankind. Others will not choose a
research career, but will make their contributions
in the clinical realm or in other forms of service.
Whatever the future holds for these talented and
dedicated students, their research experience
will remain with them for the rest of their lives,
informing their understanding of the nature and
pursuit of knowledge.

Anne N. Hirshfield, PhD
Associate Vice President for Health Research
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basic science. . .
What Role Do Androgens Play in Bone Growth?

Adrian A. Woo, MSI
Principal Investigator:
Kristine M. Wiren, PhD
Oregon Health Sciences
University, Portland, OR

Osteoporosis causes deterioration of bone tissue,
resulting in an increased fragility of bone and
corresponding increased risk of pathologic bone
fracture. Osteoporotic bone fracture, therefore,
has become a serious public health dilemma
and a leading cause of disability worldwide.1
Studies suggest a link between osteoporosis and
a hypogonadal state, potentially with reduced
amounts of circulating androgens, in both men
and women.2,3 Therefore, androgens could play
a role in the treatment of osteoporosis, yet the
specific role of androgens in bone growth and
maintenance remains unclear.
Hypogonadal elderly men appear to benefit
from anabolic steroid treatment, developing
increased lean body mass and gradual, yet
progressive, increases in bone mineral density
(BMD).4 In a separate study, treating severely
burned children with the androgen oxandrolone
also increased BMD within three to six months.5
However, studies of anabolic steroid abuse in
developing teenagers suggest stunted growth as

FIGURE 1: RATES OF BONE FORMATION IN MALE AR2.3-TRANSGENIC
MICE BY DYNAMIC HISTOMORPHOMETRY. After femurs were sectioned and polished

to 40 mm, sections were subjected to fluorescent microscopy and labels were measured. A. Bone formation
rate. B. Mineral apposition rate. C. Percentage of eroded surface. D. Percentage of labeled perimeter. Labels
were measured at both periosteal and endosteal surfaces and show a significant lack of endosteal labeling
in male AR2.3-transgenic mice. Data is shown as mean ± SEM. n = 8-20. *, p < 0.05 **, p < 0.01; ***,
p < 0.001 (vs. gender-appropriate wild-type controls).

a result of premature closing of the epiphyseal
growth plate in bone.6,7 Thus more definitive
studies are necessary to elucidate the role of
androgens in bone growth and maintenance.
To examine specific androgen effects on bone,
we genetically altered androgen receptors (ARs)
otherwise normally present in F2 populations*
of inbred mice. ARs in specific populations of
osteoblasts were altered using different sections
of the type I collagen promoter coupled to a rat
AR gene sequence. A 3.6-kb portion of the type
I collagen promoter directed AR expression in
osteoblasts throughout the lineage, from bone
marrow mesenchymal stem cells through to
mature osteoblasts, while the 2.3-kb component targeted only the mature osteoblasts.8 AR
overexpression in male AR3.6-transgenic mice
exhibited a complex phenotype, notably increased
trabecular bone mass caused by reduced osteoclast activity. Also, cortical bone expansion was
observed due to periosteal bone surface expansion, but without increased endosteal deposition.
Femoral long bones of male AR3.6-transgenic
mice demonstrated a more brittle phenotype,
partially attributable to inhibition of bone growth
on the endosteal surface.9
Overexpression of ARs in mature osteoblasts
mimics the high level of endogenous AR expression documented at this stage of differentiation.10
High-resolution micro-computed tomography
showed no differences in total cross-sectional
area. Cortical bone width and area were reduced
with increased marrow cavity in male AR2.3transgenic mice. These femurs also showed
decreased biomechanical strength and quality in
4-point bending tests, as indicated by significant
decreases in stiffness and maximum load, as well
as more dramatic decreases in post-yield deflection (brittleness) and work-to-failure (data not
shown). Dynamic histomorphometric analysis
at eight weeks showed predominantly decreased
endosteal labeling, with corresponding decreased
periosteal and increased endosteal resorption
(Figure 1C, D). Decreased bone formation and
mineral apposition rates on the endosteal surface
indicated that bone creation on this surface
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was significantly inhibited, while the periosteal
surface was not significantly affected in this
way (Figure 1A, B). These results indicate that
effects of androgens differ at these surfaces, and
are inhibitors of growth rather than anabolic
in mature bone. This study, therefore, suggests
androgen use in treatment of osteoporosis in fact
could be deleterious rather than beneficial.
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* F2 GENERATION
MICE were obtained by the

mating of F1 generation mice
showing the desired trait. The
gene was inserted into the
embryos of mice from a line of
inbred mice from Jackson Labs.

Antiproliferative Properties of Thymosin Fraction 5
in HL-60 Human Promyelocytic Leukemia Cells
For decades, the thymus gland was thought to
be a functionless, vestigial organ in mammals.
Through the pioneering work of Jacques Miller
in the early 1960s, the thymus became appreciated for its vital roles in maturing T-cells and
establishing the immune system. Shortly thereafter, Goldstein and White described the isolation of a family of hormone-like peptides from
the thymus gland collectively called thymosins.1
Since then, these small, biologically active peptides have been shown to possess important roles
in diverse physiological processes ranging from
immunomodulation to wound healing.
Interestingly, a number of these thymic peptides have anti-proliferative effects on various
human and murine tumor cell lines. This
finding, along with age-related correlations of
thymic involution and an increased frequency of
cancer, has led some to hypothesize the thymus’s
role in a possible immune surveillance mechanism of cancer suppression. Most recently, this
idea was explored in HL-60 human promyelocytic leukemia cells.
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HL-60 cells were initially derived from a
patient with acute promyelocytic leukemia, a
disease in which myeloid precursors undergo
rapid proliferation without differentiating into
mature cellular elements. This uncontrolled
growth results in an accumulation of these nonfunctioning cells in bone marrow and blood,
displacing their mature, active forms, ultimately
leading to systemic complications. Previous work
demonstrated the ability of thymosin fraction 5
(TF5), a partially purified protein extract from
bovine thymus, to substantially suppress the proliferation of HL-60 cells in both concentration
and time-dependent manners by what appears
to be a distinct, non-lethal cytostatic mechanism.3 Present efforts have been aimed at further
purifying TF5 in order to isolate the effector
peptide(s) responsible for this suppressive activity.
Purification by fast protein liquid chromatography (FPLC) followed by further purification by reverse phase high-performance liquid

LEUKEMIA CELLS

Ali A. Damavandy, MSI,
Research Track
Advisor: Mahnaz Badamchian,
PhD, Department of
Biochemistry, The George
Washington University Medical
Center, Washington, DC

Continued on p. 8
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factor (thymosin). Proc Natl Acad Sci, U.S., 1966;
56:1010–17.
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chromatography (RP-HPLC) has yielded a subfraction of TF5 which retains the anti-proliferative activity of the parent extract. The near-term
goals of this work are to sequence and chemically
characterize this peptide as well as to see if its
biological activity can be reproduced with a synthetic version of the molecule. Interestingly, the
latest flow cytometry data obtained indicates that
a significant number of the suppressed leukemic
cells do indeed undergo apoptosis. Ultimately,
elucidating the mechanism by which this peptide
exerts its action will be helpful in determining
whether it has real therapeutic potential.

2.

GOLDSTEIN AL, BADAMCHIAN M. Thymosins: chemistry and

biological properties in health and disease. Expert
Opin Biol Ther, 2004; 4:559–73.
3.

SPANGELO BL, POMPILIUS M, FARRIMOND DD, STEVENS N, NIEVA R,
SHROFF S, BADAMCHIAN M, JOHNSON CR, JARVIS WD. Presence

of a peptide component of thymosin fraction-5
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human promyelocytic leukemia cells. Int Immunopharmacol, 2005; 5:1317–29.
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SPANGELO BL, ROACH JD, HADI F, DAMAVANDY AA, PLIESKATT J,
BADAMCHIAN M. Thymosin fraction-5 possesses antipro-

liferative properties in HL-60 human promyelocytic
leukemia cells: characterization of an active peptide.
Ann N Y Acad Sci, 2007; 1112:305–16.
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ER-Targeted Bcl-2 Mitigates Ethanol Toxicity More Significantly
than Wildtype or Mitochondria-Targeted Bcl-2

Andreea G. Balan, MSI,
Research Track
Advisor: Dr. D. Blaine Moore,
Deptartment of Biology,
Kalamazoo College,
Kalamazoo, MI
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Apoptosis is the scientific term for the genetically
ethanol toxicity protection is mediated through
programmed process of cell death.1 The Bcl-2
mitochondria or inside the ER.
family of proteins, which includes both pro- and
Our team investigated whether the already
anti-apoptotic members, is responsible for the
known in vivo protection from ethanol is mediregulation of apoptosis through control of caspase
ated through ER-Bcl-2 or mitochondria — Bcl-2.
activity.1 Bcl-2
The team used three
protects cells
different fusion
from apoptosis
constructs encoding
by inhibiting Bax
for green fluorescent
and Bak (both
protein (GFP): Bcl-2
pro-apoptotic
fusion proteins were
members) from
used to examine the
releasing cytoBcl-2 subcellular
chrome c, an
localization and
important codetermination of
factor for caspase
differential rescue
FIGURE 1: ER-targeted Bcl-2 rescues CHO695 from 24 hours of ethanol
activation, from
from ethanol. A
incubation more significantly than mitochondria or wildtype-targeted Bcl-2.
mitochondria.2
line of Chinese
Student’s t-test was used to assess data significance. n=32; (*), (**) and (***)
Previously, Bcl-2
hamster ovary cells
indicate significant results with a p<0.05, p<0.01 and p<0.001, respectively. Data
was thought to
(CHO695) was
are shown as means ± standard error.
be subcellularly
transiently translocalized only
fected with GFP:
to mitochondria, however, recent work suggests
Bcl-2 wildtype plasmid, GFP: Bcl-2 MAOB
that Bcl-2 is distributed in the rough endoplasmic
(mitochondria target) and GFP: Bcl-2 Cb5 (ER
reticulum (ER) as well.3 Prior in vivo studies have
target). Fluorescence microscopy was employed
shown that overexpression of wildtype Bcl-2 proto verify the localization of the GFP: Bcl-2
tects against ethanol toxicity, a known inducer of
apoptosis.4,5 Currently, it remains unclear whether
ETHANOL TOXICITY
Continued on p. 9
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fusion proteins. Apoptosis was examined in
response to ethanol in the presence of wildtype
Bcl-2 or organelle-targeted Bcl-2 using the MTT
apoptosis assay. We tested whether the subcellular localizations of Bcl-2 to the ER and the
mitochondria would confer different levels of
rescue against ethanol toxicity. GFP: Bcl-2 fusion
proteins were appropriately localized, indicating
successful organelle-targeting. Our in vitro
model system confirmed the protective role of
Bcl-2 wildtype against ethanol toxicity previously shown only in vivo.4,5 Moreover, we found
that the ER-targeted Bcl-2 significantly rescued
CHO695 cells from ethanol toxicity, even at
normally toxic concentrations, whereas wildtype
and mitochondria-targeted Bcl-2 offered more
limited protection (Figure 1). The same results
were confirmed in another line of Chinese hamster ovary cells (CHO-Pro5) as well.
Therefore, our findings indicate that Bcl-2’s
known amelioration of ethanol toxicity is likely
mediated through pathways in the ER. Such
results could be utilized to elucidate a possibly new apoptotic pathway in which the ER
is upstream of the mitochondria and in which
Bcl-2 embedded in the ER membrane inhibits

Bax translocation to the mitochondria. Research
attempting to understand cellular changes
induced by ethanol toxicity, and aiming to
exploit a cell’s own defense mechanism, could
ultimately lead to treatments preventing alcohol
toxicity.
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A New Focus in Breast Cancer Bone Metastasis:
NF-κB Gene Suppression
Breast cancer is the most common malignancy
seen in women. As many as one-third of women
with early-stage breast cancer will die, with
most developing complications arising from
bone metastases, including severe pain, spinal
cord compression and pathologic fracture.1,2 In
conjunction with the Center for Musculoskeletal
Research and Department of Biomedical
Engineering at the University of Rochester
Medical Center, a novel way of suppressing this
tumor burden in bone was discovered.
This required a tremendous appreciation for
bone biology and how certain breast cancers
prefer particular metastatic sites. In fact, some
breast cancers uniquely display osteotropism, a
significant ability to proliferate in bone.1 These
breast cancers with a preference for bone and the
potential host metastatic site must each possess
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intrinsic biological properties favoring mutual
attraction between one another.3 As early as 1889,
Paget put forth the “seed and soil” hypothesis
that embodies this phenomenon, referring to the
bone microenvironment as a fertile, rich “soil” in
which breast cancer cells may grow as “seeds.”4
A clinical hallmark of disrupted bone remodeling in aggressive breast cancers is osteoclastmediated bone destruction.1 Osteoclasts are
bone-resorbing cells native to bone which are
activated in response to cytokines produced by
breast cancer cells.5 Production of these cytokines is tightly controlled by the nuclear factor-κB
(NF-κB) transcription factor.6
Targeting the NF-κB pathway holds significant promise in treating various cancers and
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diseases associated with abnormal bone resorption.7,8 Since patients with bone cancers possess
much lower relative survival rates than patients
with soft tissue cancers,9 verifying a target such
as NF-κB, governing production of an array of

of the proinflammatory, bone-resorbing
cytokine interleukin-6 (IL-6), and in vitro bone
resorption by tumor/osteoclast co-cultures
while reciprocally up-regulating production of
the apoptotic enzyme caspase-3. Suppression
of NF-κB transcription in these breast cancer
cells also suppressed in vivo tumor-mediated
bone destruction after intratibial injection of
tumor cells in female immunosuppressed mice.
Immunohistochemistry showed the resorptive
lesions formed in bone by MDA-MB-231 cells
express both the p65 subunit of NF-κB and IL-6
at the bone-tumor interface.10 Taken together,
these findings demonstrated an essential role
for NF-κB signaling in breast cancer-mediated
bone destruction. Strong rationale now exists to
further investigate genetic and pharmacologic
NF-κB inhibitors as standard or adjuvant
therapies in these regards.
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FIGURE 1: THE “VICIOUS CYCLE” OF CANCER-MEDIATED BONE
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cells to home in on bone, adhere to the bone linings and seed in the bone microenvironment. The tumor
cells then secrete cytokines (i.e., PTHrP, TNFa, IL-1, IL-6, and IL-11), many of which are controlled by
NF-κB signaling. This stimulates bone resorption by osteoclasts via osteoblast production of RANKL. Matrix
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biological factors relevant to metastatic progression in bone, can be of great value.
The bone-seeking MDA-MB-231
Targeting the NF-κB
breast cancer cell line was genetically
altered to suppress NF-κB-mediated
pathway holds significant gene expression. In its inactive
state, NF-κB is bound to an IκB
promise in treating varprotein within the cytoplasm of
ious cancers and diseases cells. Phosphorylation of IκB frees
NF-κB to move to the nucleus of cells
associated with abnormal to perform NF-κB-mediated gene
transcription.6 A single-point mutation
bone resorption.7,8
of IκB (replacing one serine amino
acid for an alanine) was stably infected
in these breast cancer cells to prevent this
phosphorylation and associated gene expression.10
Blocking NF-κB signaling in MDA-MB-231
cells decreased in vitro cell growth, expression
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Certain Piperazines Mimic Stimulant or Hallucinogenic
Effects of Ecstasy

Users of 3,4-methylenedioxymethamphetamine
hallucinogen-like effects of BZP, MeO-BZP,
(MDMA, “ecstasy”) report the drug elicits
TFMPP, and m-CPP.6,7 All N-substituted
a complex array of subjective effects, some
piperazines were tested for locomotor stimulant
1
stimulant-like and others hallucinogen-like.
effects in a modified open field apparatus, and
Usage of MDMA has increased worldwide,
mice trained to discriminate S(+)-MDMA
particularly among young adults.2 While
or R(-)-MDMA from saline were tested for
regulatory control of MDMA exists in the
stimulus generalization to all of the N-substituted
United States, federal law enforcement agents
piperazines.
continue to encounter and confiscate MDMA
The results of the current study indicated
3
across the country. In addition to widespread use
that BZP, TFMPP, and m-CPP dose dependently
of MDMA itself, certain “ecstasy” tablets also
could fully substitute for S(+)-MDMA, but could
contain N-substituted piperazines which mimic
not elicit R(-)-MDMA-like stimulus effects. In
the effects of MDMA.4
contrast, m-MeO-BZP dose dependently could
This study investigated how certain
partially substitute for both enantiomers. BZP
N-substituted piperazines, in comparison with
profoundly stimulated locomotor activity, but did
MDMA enantiomers, may affect classical
not elicit a significant head twitch response, while
stimulant and
hallucinogenic
FIGURE 1: SUMMARY OF EXPERIMENTAL RESULTS.
behaviors in
Drug
Head Twitch
Locomotor
S(+)-MDMA
mice trained to
				
Discrimination
discriminate either
S(+)-MDMA or
BZP
No
Increase
Full
R(-)-MDMA from
saline. Previous
MeO-BZP
No
Decrease
Partial
studies suggest
TFMPP
Yes
Decrease
Full
that the effects of
S(+)-MDMA are
m-CPP
No
Decrease
Full
more stimulantlike than those of
R(-)-MDMA, while the actions of R(-)-MDMA
TFMPP elicited a dose dependent head twitch
are more hallucinogen-like than those of the
response but only suppressed locomotor behavior.
S(+)- enantiomer.5
Neither m-MeO-BZP nor m-CPP elicited head
In a murine model, various N-substituted
twitch behavior, as both compounds decreased
piperazines were administered and evaluated
locomotor activity dose dependently.
for head twitch response (a hallucinogen-like
Of all the N-substituted piperazines studied,
drug effect), increased locomotor activity
only BZP exhibited a clear stimulant-like
(a stimulant-like drug effect) and MDMApattern of behavioral effects, while only TFMPP
like discriminative stimulus effects in mice
exhibited hallucinogen-like effects in the head
(analogous to subjective drug effects in humans).
twitch assay. Based on the present findings,
Various doses of l-benzylpiperazine (BZP),
m-MeO-BZP and m-CPP cannot be described
1-(3-trifluoromethylphenyl) piperazine (TFMPP),
as stimulant-like or hallucinogen-like in the
1-(3-methoxybenzyl) piperazine (m-MeO-BZP)
mouse. Still, various N-substituted piperazines
or meta-chlorophenyl piperazine (m-CPP) were
demonstrate differing ecstasy-like drug effects
administered to mice to determine the effects on
in a murine model, and warrant further
these behavioral endpoints.
investigation and monitoring with regard to their
The head twitch response is sensitive
addiction and abuse potential.
2
to serotonin 5-HT agonist activity in the
rodent and was therefore used to evaluate the
ECSTASY
Continued on p. 12
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they vigorously process sensory information. In
fact, the sensory cortical organization of higher
mammals is one in which primary processing
areas are typically surrounded by secondary or
higher-level processing areas.
In the cat brain, the lateral suprasylvian
sulcus (LSS) contains representations of the
visual modality thought to be exclusively
populated by visual-specific neurons.1,2 The
visual LSS is laterally bordered by the dorsal zone
of auditory cortex; recent electrophysiological
experiments document the presence of auditory/
visual bimodal cells in what otherwise
appears to be the visual
LSS.3,4 While the sensory
function of the LSS
cells has been
expanded with
this finding,
the transition/
multisensory
zones between
auditory and
visual regions have
not been defined. It
FIGURE 1. ORTHOGRADE PROJECTIONS FROM AI TO LSS. Injections of tracer is not known whether
result in labeled axons and terminals in the lateral bank of the LSS. Coronal sections are arranged from the
AUDITORY
left, anterior to posterior. Grey regions indicate location and extent of injection; each black dot represents
a single bouton or axon terminal. Inset on left indicates the cortical level from which each coronal section
PROJECTIONS
originates. Scale bar = 1mm.
Continued on p. 13
A fundamental organizational feature of the
mammalian brain is the arrangement of sensory
representations in the cerebral cortex. The
cortical representation of vision is localized
in the occipital lobe, auditory in the temporal
lobe and somatosensory in the parietal lobe.
Studies of a wide variety of mammals indicate
a primary thalamic-recipient area for each
sensory modality, designated as the primary
sensory cortex. Most textbook depictions of the
sensory representations show a large gap between
locations of the primary sensory representations.
However, these areas are not inactive, but rather
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AUDITORY PROJECTIONS
Continued from p. 12
there is a distinct border marking the edge
between the two different representations, or if
there is a gradual transition yielding a substantial
area in which representations of both modalities
overlap. In the latter case, inputs from different
modalities that overlap within a given area
can converge onto individual neurons, thereby
inducing multisensory properties.5
This problem was addressed in our study by
labeling auditory projections to the LSS of the
cat using neuroanatomical tract tracing methods.
Adult cats (n=17) were anesthetized and,
using sterile surgical techniques, biotinylated
dextran amine (BDA) was injected into one of
the following auditory cortical areas: anterior
auditory field (AAF), primary auditory cortex
(AI) or posterior auditory field (PAF). Standard
cytochemical procedures were used to visualize
the transported tracer and a computer-based
digitizing microscope was used to plot the
location of labeled axon terminals. In each
case, labeled boutons were identified in the LSS
region. Labeled terminal boutons were most
concentrated at the outer lip of the LSS and the
label became progressively reduced with depth
along the lateral bank of LSS toward the fundus,
as shown in Figure 1, for AI auditory projections
to the LSS (each black dot=1 labeled bouton).
This steady decrease in auditory projections
down the bank of the LSS, as opposed to
an abrupt demarcation, indicates a gradual
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transition from auditory to visual sensory
modality.
Although the LSS has widely been regarded
as a visual area of the cat cortex, these results
show that multiple auditory cortical projections
target the region in a gradated manner. Auditory
projections are quite dense at the external lip of
the sulcus and are gradually reduced within the
depth of the bank of the LSS. Ultimately, the
broad distribution of auditory input suggests that
substantial portions of the visual LSS region may
be a site of multisensory (visual and auditory)
convergence. These overlapped projections may
provide the anatomical basis for multisensory
properties of neurons in higher mammals.
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The overarching goal of the Bone Health
volume phenotypes. Although the study cohort
Program at Children’s National Medical
had not participated in resistance training for
one year, we found that individuals with the
Center, in Washington, DC, is to contribute
rare alleles consistently had the greatest baseline
answers to the questions, “What makes bone
strong?” and “can we make bones stronger?”
muscle strength and lowest subcutaneous fat
More specifically, the program seeks to identify
volume. Strikingly, while the presence of the
genetic variations that will help individuals
rare allele predicted baseline values of muscle
better understand their risks for bone health and
strength and fat volume, it did not predict
disease, while simultaneously providing them
significantly higher values of muscle hypertrophy
with recommendations for healthy behaviors that
or gained strength after resistance training. This
can reduce their risks of serious
disease. To help achieve this goal,
… [I]ndividuals with the rare alleles
the Bone Health team partnered
with Dr. Eric Hoffman, director
consistently had the greatest baseline muscle
of the Research Center for Genetic
strength and lowest subcutaneous fat volume.
Medicine, to develop a program
that explores answers to these
suggests that the ability of muscle to hypertrophy
questions in the clinic, operating room and
and gain strength are controlled by genes other
laboratory.
than CCL2 and CCR2.1,2
Our Gill Fellowship summer projects were
In addition to providing a research
devoted to the study of chemokines. Chemokines
experience, our fellowships also presented the
are a large group of proteins that act as lures
opportunity to observe patient care in the
to attract white blood cells and are involved
orthopaedic outpatient clinic and operating
in various disease processes, including acute
room. More over, we traveled to the International
and chronic inflammation, infectious diseases
Conference on Children’s Bone Health in
and cancer. Although primarily associated
Montreal, Canada, to gain greater exposure to
with disease, the inflammatory response is also
international research efforts in bone health.
associated with muscle repair, regeneration and
1
growth. Muscle strength, as well as exercise,
REFERENCES:
contributes to bone strength. The CC family of
1. TIDBALL J. Inflammatory processes in muscle injury
chemokines is the largest of its kind, and one of
and repair. American Journal of Physiology —
the most thoroughly characterized chemokines
Regulatory Integrative and Comparative Physiology,
is CCL2.1 CCL2 and one of its major receptors,
2005; 288:R345–53.
CCR2, are encoded by genes CCL2 and CCR2,
2. YU X, DLUZ S, GRAVES D, ZHANG L, ANTONIADES H, HOLLANDER
respectively. Given the widespread effects of
W, PRUSTY S, VALENTE A, SCHWARTZ C, SONENSHEIN G.
CCL2 and CCR2, our goal was to investigate
Elevated expression of monocyte chemoattractant
whether variants of the genes CCL2 and CCR2
protein 1 by vascular smooth muscle cells in
hypercholesterolemic primates. Proceedings of the
influence skeletal muscle, bone and subcutaneous
National Academy of Sciences of the United States of
fat volume at baseline and after resistance
America, 1992; 89:6953–57.
training in healthy young adults.
Blood DNA samples and MRI images were
obtained from the Functional Polymorphisms
Associated with Muscle Size and Strength
study of more than 1,200 college students
enrolled in a 12-week resistance training
program. Investigating the influence of genetic
polymorphisms on bone geometry, fat volume,
and skeletal muscle size and strength, variants in
CCL2 and CCR2 were found to correlate with
specific skeletal muscle and subcutaneous fat
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Cloning and Expression of Human Adenovirus
Precursor Protein VI and Mature Protein VI
There are 47 serotypes of the human adenovirus
that are responsible for a group of respiratory
diseases, including, but not limited to, 30
percent of all colds, pneumonia and bronchitis,
in addition to gastroenteritis, viral pink eye and
cystitis.1 Epidemiological studies indicate an
adenoviral agent as the cause of 5–10 percent of
juvenile pneumonias and respiratory infections
of children in North America.2 Respiratory
infection with adenoviruses is also regularly
responsible for a number of infant deaths and
considerable morbidity among some adult
populations. Serological prevalence studies
suggest that the average individual undergoes
a minimum of two or three clinical episodes
of adenoviral infection during childhood.2 In
addition, human adenovirus is one of the leading
opportunistic infections that are a major cause
of death in patients with Acquired Immune
Deficiency Syndrome (AIDS) and deficient
immune systems.3
The human adenovirus proteinase (AVP)
is required for the development of infectivity.4
AVP is synthesized by the adenovirus and
packaged into nascent virus particles. When
activated, AVP cleaves virion precursor
proteins, thereby rendering the virus particle
infectious. AVP requires two viral cofactors for
maximal activity — adenovirus DNA and an
11-amino-acid peptide, known as pVIc, derived
from the C-terminus of precursor protein VI
(pVI). Protein VI also functions as a precursor
“scaffolding” protein that plays a critical role
in the assembly and maturation of the virus
particle.5
The synthesis and investigation of the
precursor and mature form of protein VI is
essential because of its critical role in producing
the pVIc cofactor required for proteinase
activation and subsequent viral infection. To
characterize the interactions of AVP and DNA
that render the virus particle infectious, the
genes for pVI and VI must be cloned, expressed
in bacterial hosts and the resultant recombinant
proteins purified. There is no evidence that pVI
or VI has been successfully cloned or expressed
prior to this experiment.
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This experiment established a novel, stepwise
protocol for cloning pVI and VI genes and
expressing the proteins in bacterial hosts. The
genes for pVI and VI were successfully amplified
from genomic adenovirus DNA, digested with
restriction enzymes, ligated into prepared pET
Michelle Louie, MSI
expression plasmids and transformed into
Research Track
bacterial hosts. PCR of the purified plasmids
Advisor: Walter F. Mangel, PhD
verified successful cloning of the correct gene
Brookhaven National
sequences. Proteins pVI and VI were then
Laboratory, NY
expressed in BL21-codon plus(DE3)-RIPL cells
grown in ZYM-5052 auto-inducing medium. A
15 percent SDS-PAGE and an assay using AVP
and Rhodamine fluorogenic substrate confirmed
successful protein pVI and VI expression.
A supply of purified recombinant proteins
pVI and VI was produced, purified and stored
for future research. The end
products of this investigation
The end products of this
will be significant in
developing drug targets for
investigation will be significant
anti-viral agents and providing
information for the study of
in developing drug targets for
other viruses with congruent
anti-viral agents … .
activation mechanisms.
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The Role of Retinoic Acid in Neuronal Phenotype Determination
An important element of the developing central
nervous system is the acquisition of specific neuronal phenotypes. Retinoic acid plays a fundamental role in CNS development and is essential
for normal growth of the embryo. The effect
of retinoic acid on neurotransmitter phenotype
determination can be analyzed by examining the
expression patterns of specific molecular markers.
The expression of a gamma-aminobutyric
acid (GABA)ergic or glutamatergic neuron can
Negin Daneshpayeh, MSI
be examined in a model vertebrate organism
Advisor: Margaret Saha, PhD
such as Xenopus laevis, the African clawed
Department of Biology
frog. GABAergic neurons release GABA, the
The College
most abundant inhibitory neurotransmitter in
of William and Mary
the CNS, and glutamatergic neurons release
Williamsburg, VA
glutamate, the most abundant excitatory
neurotransmitter in the CNS. In order to
visualize the expression patterns, wholemount in situ hybridization was performed to
examine the spatial
expression of specific
It is believed that retinoic acid plays
molecular markers
a fundamental role in the acquisition during various
stages of embryo
development.1,2 The
and patterning of GABAergic and
xGAT1 and xVGlut1
glutamatergic phenotypes. Retinoic
RNA probes allowed
visualization of the
acid comes from the family of retinexpression patterns
of GABAergic
oids and has been correlated with
and glutamatergic
neurons, respectively.
causing birth defects in newborns,
Normal expression
both when deficient and when present of xGAT1 is first
observed at late
in excess.
neurula stages in the
anterior portion of
the developing spinal cord.3 By tailbud stages,
bilateral xGAT1 expression is apparent in all
regions of the CNS, including distinct regions of
the forebrain, midbrain, hindbrain and olfactory
placodes.3
Normal expression of xVGlut1 is first
detected at late neurula to early tailbud
stage embryos with prominent expression in
the developing trigeminal nerve and in the
developing spinal cord.4 By later tailbud stages,
xVGlut1 mRNA is observed in the pineal gland,
the olfactory placodes and more posteriorly in
the trigeminal and facial cranial nerves.4
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It is believed that retinoic acid plays a fundamental role in the acquisition and patterning
of GABAergic and glutamatergic phenotypes.
Retinoic acid comes from the family of retinoids and has been correlated with causing birth
defects in newborns, both when deficient and
when present in excess. These include abnormalities in facial bone structure, in the ears and
eyes, and in brain mass. Retinoic acid acts as a
signaling molecule regulating critical processes
during early development, including axial patterning, cellular differentiation, tissue induction,
proliferation and apoptosis.5 The natural concentration of retinoic acid in the body is crucially
important and is constantly regulated.
In Xenopus development, retinoic acid
becomes important at the beginning of gastrulation (stage 10 of development two). This stage
marks the point at which segregation of body
layers begins to take place. It is known that
excess concentrations of retinoic acid in the
environment affect the formation of the neural
tube. More specifically, the effect appears to be a
truncated anterior of the CNS.
It is hypothesized that the expression patterns
of the neurotransmitter markers will be altered
by the presence of excess retinoic acid. To test
this hypothesis, Xenopus embryos were exposed
to various solutions of retinoic acid at different
developmental stages.2 In situ hybridizations
were conducted, with xGAT1 and xVGlut1 RNA
probes. Whole mount examination revealed
obvious malformation in the embryo. The effect
on expression patterns of the molecular markers
needs to be further analyzed via histological
sections. More specific findings regarding the
role of retinoic acid and its affects on expression
patterns of GABAergic or glutamatergic neurons
will help in understanding the acquisition of a
specific neuronal fate. Furthermore, it will help
in understanding the development of congenital
birth defects in humans.
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A Potential Role for DHEA in Prostate Cancer
Dehydroepiandrosterone (DHEA) is the most
abundant endogenous steroid produced by the
adrenals of men and women, although levels
decline markedly with age. DHEA is increasingly consumed as a commercial nutritional
supplement for its purported anti-aging effects,
yet its usefulness, long-term safety and effects
remain uncertain.1
DHEA can be metabolized by the prostate
gland and can increase expression of secondary
mediators for epithelial growth and differentiation. Furthermore, because it is a precursor
to both estrogens and testosterone, controversy exists as to whether DHEA enhances
or reduces the risk of prostate cancer.2 Since
supplements are not regulated by the Food and
Drug Administration, The National Center
for Complementary and Alternative Medicine
(NCCAM) at the National Institutes of Health
(NIH) plays a vital role in researching the effects
of supplements such as DHEA.
Prostate cancer is the second most common
type of cancer among men in the United States,
and approximately one out of three men will
become afflicted.3 The prostate epithelium
contains glandular cells that synthesize and
secrete products of seminal plasma, including
prostate-specific antigen (PSA), the major
diagnostic marker for prostate cancer. These
epithelial cells depend on androgenic stimulation for their viability and secretory ability and
become malignant during prostate cancer. They
are surrounded by a fibromuscular stroma that
not only physically supports the glands, but
also contributes to the endocrine and paracrine
microenvironments of these cancer cells. Thus,
the stromal cells help control the growth and differentiation of the epithelial cells, as well as play
a critical role in mediating the responsiveness
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of these cells to steroid hormones.4 My research
aimed to determine what specific factors these
stromal cells produced in response to DHEA and
provide insight into how the stromal environment modulates conversion of healthy epithelial
cells into malignant prostate cancer.
Prostate epithelial cancer cells were cocultured with stromal cells and separated by a
substance called Matrigel, which functioned like
a permeable basement membrane, allowing the
passage of soluble stromal mediators to the epithelial cells. After the cells were grown, treated
with DHEA and harvested, the co-cultured
stromal RNA was extracted. Subsequently,
cDNA was synthesized and real-time reverse
transcriptase PCR was performed to measure
expression of 84 genes related to human growth
factors.
Results from three separate experiments were
comparable and showed the up-regulation of
several specific genes, including FGF-1 (fibroblast
growth factor), IGF-1 (insulin-like growth factor),
FGF-7 (fibroblast growth factor) and HPRT-1
(hypoxanthine phosphoribosyltransferase). While
these results are preliminary, they may provide
some insight into what growth factors the stromal
cells produce in response to DHEA and can be
further explored as targets for stromal regulation
of epithelial cell function. My research experience
only scratched the surface investigating the role
of DHEA in prostate cancer, but I gained useful
research experience and am optimistic about
NCCAM’s future efforts on this important topic.
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Otitis media (OM), an inflammation of the
middle ear, is a ubiquitous condition of early
childhood accounting for 16 million physician
office visits each year. OM is associated with
hearing loss, delayed speech development and
the potential for permanent middle ear damage.
Environmental agents such as tobacco smoke
have been shown to be a risk
factor in the occurrence of OM
in early childhood.1 OM can
be classified by its associated
clinical symptoms, otoscopic
findings, complications and
duration. There are two classifications of OM, acute and
chronic, which differ in duration and result from different
etiologies. Acute OM often
results from upper respiratory
infections; whereas chronic
OM is usually non-infectious
and thought to be due to
chronic inflammation and
mucous hyper-secretion. Environmental agents
such as cigarette smoke are highly correlated
with the occurrence of chronic OM. Studies
conducted by different federal agencies suggest
exposure to tobacco smoke may be a significant
risk factor in the development of chronic OM in
early childhood. The direct mechanism by which
cigarette smoke exposure results in OM remains
under investigation.
The etiology of OM inflammation within
the middle ear mucosa is primarily initiated,
mediated and regulated by pro-inflammatory
cytokines: TNF-α, IL-1β, IL-6 and IL-8.2 The
inflammatory cascade is initiated by micro-

organisms and/or their products, leading to
an increase in restrictive oxygen species (ROS)
and causing activation of the NF-κB complex.
NF-κB translocates to the nucleus and transcribes genes encoding for ICAM-1, TNF-α,
IL-1β and several secondary pro-inflammatory
cytokines.

Cigarette smoke induces pro-inflammatory
cytokines in the lower respiratory system, and
exposure of cigarette smoke to the rat lung
induces redox-sensitive transcription factors
NF-κB and AP-1, which are linked to the
transcription of specific inflammatory cytokines
and chemokines.3 Cigarette smoke also induces
the synthesis of glutathione and gammaglutamylcysteine that is associated with AP-1 or
an AP-1 like response element.3 In addition to
increasing transcription of inflammatory genes,
cigarette smoke also decreases HDAC2 activity
in the rat lung, in turn decreasing histone
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deacetylation, and thus increasing transcription
of pro-inflammatory genes.
We hypothesized that cigarette smoke
condensate (CSC) stimulation would activate
NF-κB and ultimately increase pro-inflammatory
cytokine secretion in mouse middle ear epithelium cells (mMEEC).
To investigate our hypothesis, we used a
mouse inflammatory antibody array to measure
40 different pro-inflammatory cytokines from
CSC stimulated mMEEC. The mMEEC was
stimulated with 0 micrograms per microliter, 20
micrograms per microliter and 40 micrograms
per microliter CSC for two, eight and 24 hours,
respectively. The inflammatory antibody array
was analyzed with chemiluminescence imaging.
We observed a significant increase in pro-inflammatory cytokines IL-6, TNF-α, IFN-γ, IL-4 and
IL-13. We plan to further analyze these cytokines

of interest using Enzyme Linked Immunosorbent
Assay (ELISA) kits to confirm our findings.
In conclusion, CSC activated pro-inflammatory cytokine secretion in mMEEC in vitro.
These findings will bring us closer to understanding the biological mechanism responsible for
the high correlation of OM with young children
exposed to second-hand smoke.
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Development of an In Vitro Model
of Respiratory Tract Submucosal Glands
A mucosal layer protects the respiratory tract
epithelium against pathogens and environmental
toxins. Mucin glycoproteins (mucins) are
overproduced in chronic diseases of the
respiratory tract, such as cystic fibrosis (CF) and
chronic rhinosinusitis
(CRS), and contribute
significantly to disease
morbidity and mortality.1
Mucous hypersecretion
predominantly
results from goblet
cell hyperplasia and/
or submucosal gland (SMG) hyperplasia. In
vivo and in vitro model systems are used to
investigate mechanisms of mucin hypersecretion
in the conducting respiratory tract epithelium.
However, there is no established in vitro
glandular model for the submucosa.
Presently, the standard in vitro models consist
of differentiated primary human bronchial
epithelial (HBE) or nasal epithelial cells grown
on transwell plates coated with collagen at an
air-liquid interface. Within two weeks, these
cells differentiate into a conducting respiratory
tract epithelium with cilia, basal and goblet
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cells.2,3 The models secrete both MUC5AC
and MUC5B mucins, which are in vivo
markers for goblet cells and submucosal glands,
respectively.4 However, these cell models do
not develop glands, although they are clearly
pluripotent and express
FIGURE 1: Microscopic view glandular proteins. We
of gland-like structure formed
hypothesized that HBE
by H-Tert immortalized tracheal
cells would develop
bronchial epithelial cells when
glands if grown in the
grown mixed with Matrigel on
appropriate context.
Day 9 after plating.
Submucosal glands
are invaginations of
the epithelium and are composed of ductal and
secretory cells (both mucous and serous) that
secrete mucins and host defense proteins into
the mucosal layer. Cells from various tissues
have already been shown to develop intestinal,
mammary, salivary, pancreatic or oviduct glands
when grown on Matrigel, a basement membrane
complex isolated from murine tumors.5,6 The
main component of Matrigel is laminin, as
well as collagen type IV, heparan sulfate and
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and Diego Preciado, MD, PhD
Children’s National Medical
Center, Washington, DC

SUBMUCOSAL GLANDS MODEL
Continued on p. 20

19

SUBMUCOSAL GLANDS MODEL
Continued from p. 19
proteoglycans. At 37° C, Matrigel forms a threedimensional gel that supports cell morphogenesis
and differentiation.7 Currently, there are no
reports of respiratory tract gland (submucosal
gland) development using Matrigel.
Two different approaches were used:
respiratory tract-derived cells were either
grown on top of, or mixed with, Matrigel.
Cell media was changed as required and cells
were periodically monitored by microscopy.
Experiments were carried out using three
different cell lines, including Calu-3 cells (cancer
cell lines of SMG origin), H-Tert immortalized
tracheal bronchial epithelial cells and normal
human bronchial epithelial (HBE) cells.
Our preliminary results showed that
respiratory tract-derived cells formed glandularlike structures but did not differentiate further
after five days. A literature review indicates that
epithelial cells from various tissues require seven
to 15 days of growth on Matrigel to differentiate
into glands, with subsequent apoptosis to form
a glandular lumen.7,8 Our data indicated that
under these conditions, respiratory tract cells do
not undergo apoptosis to form a lumen. Future
experiments will focus on inducing apoptosis
in order to facilitate differentiation of SMG
and thus establishment of an in vitro model to
investigate SMG development and hyperplasia in
respiratory diseases such as CRS and CF.
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A Three-Dimensional Model of Epicardial Development
Development of the epicardium is critical to
proper heart formation. The epicardium provides
all of the precursor cells that form the coronary
system and supplies signals that stimulate cardiac
myocyte proliferation. The epicardium forms
from mesothelial cells (proepicardial [PE] cells)
associated with the developing liver. Here, a
model of epicardial development is presented. PE
cells have been isolated from chicken embryos
and cultured on a 3-D scaffold. This 3-D model
system consists of a tubular scaffold engineered
from type-I collagen and optimized to support
the growth of embryonic cardiac tissues.1,2,3
Using scanning electron microscopy (SEM),
we compared in vivo PEs with PEs cultured on
the tube scaffold for three days. In vivo PE cells
appeared as cobblestone cells covering the AV
sulcus of HH stage-17 chicken hearts as well as
the outflow tract of the heart. Cells on the tube
also were observed to migrate as a sheet and
possessed apical villi characteristic of in vivo
PE cells.4 Similarly,
PE cells cultured
on the tube scaffold
displayed a cobblestone
morphology and
possess apical villi.5
SEM data also revealed
PE cells could migrate
in a sheet-like fashion
and inhabit pit-like
areas of the tube
scaffold.5 Moreover,
PE cells cultured on
the collagen scaffold
clearly maintained
their morphological
characteristics and
closely resembled their
in vivo counterparts.
Cultured PE cells also
expressed markers for
both endothelial and
smooth muscle cells,
bearing a striking
resemblance to in vivo
cells undergoing
vasculogenic
processes.5 Taken
together, these data
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support the tube scaffold as a viable model for
epicardial development.
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FIGURE 1: COMPARATIVE
MORPHOGENESIS OF THE
PROEPICARDIAL CELLS. A, B,

C, E, G: Representative proepicardium (PE)
morphogenesis in the stage-17 chicken embryo.
A: Stage-17 chicken embryo showing the
branchial arches (BA), heart tube (HT) and the
proepicardium (PE). B: Higher magnification
of (A) showing the PE extending from the
liver toward the heart tube (HT). C: PE cells
migrate as a sheet from the atrioventricular
sulcus toward the outflow tract. The dashed
line indicates the boundary of migrating cells.
D, F, H: Representative images of PE cell
morphogenesis on the tubular scaffold.
D: Chicken PE cells cultured on the collagen tube
exhibit a cobblestone appearance. The dashed
line identifies the boundary of migrating PE cells
on the collagen tube. E: Higher magnification
of (C) shows that the in vivo cells migrate as a
sheet over the HH stage-18 chicken heart.
F: PE cells exhibit a cobblestone morphology and
are found in pit-like areas of the tube scaffold.
G, H: Arrows show the presence of apical villi
on the surface of PE cells in vivo and on the
collagen scaffold in G and H, respectively (scale
bars equal 100 μm in A-C and 10 μm in D-H).
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clinical practice. . .
Improving MRI Detection of Creutzfeldt-Jakob Disease

Andrew Degnan, MSI
Research Track
Principal Investigator, Mentor:
Isak Prohovnik, PhD;
Hedok Lee, PhD,
Mount Sinai School
of Medicine, NY

Creutzfeldt-Jakob
disease (CJD) is a rare
neurodegenerative
prion disease characterized by the accumulation of abnormal
prion protein leading
to neuron loss, vacuolation and/or astrogliosis. CJD is characterized by rapid-onset
dementia, rapid degen- FIGURE 1: DIFFUSION COEFFICIENT (ADC) MAPS OF PATIENTS WITH CJD.
Comparing ADC maps of patients with controls showed more significant reductions in ADC within the thalamus
eration and death. In
this study, Libyan-born and striatum using b=2000, suggesting greater sensitivity with high b-value (right).
Israelis at increased
a voxel-based statistical software package.
risk for the inherited form of CJD were examined
Comparisons were examined using Apparent
at Sheba Medical Center (Tel Hashomer, Israel).
Diffusion Coefficient (ADC) maps, a quantitative
The patients suffered from either familial or spomeasure of proton diffusion capable of providing
radic CJD. Our group previously reported similar
more robust statistical comparison. The comparradiological findings for familial cases when com1
ison of control subjects to CJD patients showed
pared to the more common sporadic form.
greater sensitivity to basal ganglia and thalamic
This study analyzed two diffusion-weighted
changes using high-value sequences, while the
(DWI-MRI) sequences to evaluate the sensitivity
2
lower b-value detected more cortical changes.
of higher b-value DWI (b=2000 s/mm ), as
These findings suggest greater diffusion-weighted
compared with the more common lower b-value
2
MRI sequences may be advantageous in detecting
sequence (b=1000 s/mm ). DWI-MRI measures
CJD-related changes.
differences in proton movement indicative of
tissue structure, and it has been demonstrated to
be an early marker of CJD-related pathology with
better sensitivity and specificity than other CJD
criteria such as the cerebrospinal fluid 14-3-3
protein detection and EEG patterns.2 DWI-MRI
patterns in CJD patients typically include hyperintensities within the caudate nucleus, putamen,
thalamus and cortical ribbon; these findings
putatively correspond to vacuole formation, the
hallmark histological finding of prion diseases.3
B-value is a function of diffusion gradient
strength; a higher b-value is thought to be more
sensitive to diffusion and has been used with success in detecting other diseases.4 A high b-value
DWI may provide earlier detection of CJD
pathogenesis and improve understanding of the
progression of imaging changes.
DWI scans of 10 patients and age- and
gender-matched controls were analyzed using
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Small Molecules that Induce p53 Signaling in
Retinoblastoma Preclinical Animal Models
Retinoblastoma is an intraocular malignancy
that occurs in children when a germline
mutation of RB1 is inherited and a somatic
mutation inactivates the second RB1 allele.1
Common modes of treatment to preserve vision
include triple-drug chemotherapy, radiation,
laser and cryotherapy. When chemotherapy
is combined with focal treatments, up to
40 percent of patients do not respond and
enucleation of the eye may be required to prevent
metastatic retinoblastoma which is often fatal.2
Current drugs have undesirable side effects,
including an increased risk of developing acute

Institute library that were previously shown
to induce p53 in other types of cancer cells,
we screened and selected small molecules that
demonstrated cytotoxic effects in retinoblastoma
cells.
One such p53 activator investigated was
a small molecule that “Reactivates p53 and
Induces Tumor cell Apoptosis” (RITA). In
previous studies, RITA was shown to suppress
the growth of osteosarcoma and fibro-sarcoma
cells.6 By analyzing the effects of RITA in RB1
tumor growth assays, RITA demonstrated potent
cytotoxic effects. We calculated the 50 percent
growth inhibitory
concentration
MS-275 IN OCULAR XENOGRAFT MODEL
(GI50) from in vitro
experiments, and
correlated growth
VEHICLE
inhibition with Western
Blot analyses. This
data demonstrates
suppression of cell
MS-275
proliferation while
up-regulating p53 gene
expression.
FIGURE 1: Y79-LUC CELLS WERE TRANSPLANTED INTO THE
To recapitulate
VITREOUS OF DAY-OLD RATS. On day-14 post-transplant the animals were treated
the
tumorgenicity
by intraperitoneal injection of 20 mg/kg MS-275 or vehicle for 12 days (six treatments total) and
properties
of RB1
injected with 150 mg/mL D-Luciferin for imaging with the IVIS Lumina imaging system.
in animals, we used
an ocular xenograft
myeloblastic leukemia or hearing loss from
rat model. Human retinoblastoma cells were
ototoxicity.2,3 Since retinoblastoma is a rare
transplanted directly into the eyes of newborn
disease (300 new cases in the United States each
rat pups to establish tumor growth. Using a
year), preclinical animal models that recapitulate
microscope and the tip of an insulin syringe,
the tumorgenicity are important for developing
the eyelids of anesthetized rat pups were
4
new chemotherapy treatments.
surgically opened and the posterior chamber
The tumor suppressor RB1 gene is
was infused with cultured cells. Tumor growth
responsible for regulating cell proliferation, while
was established over 14 days and the rats were
the p53 gene regulates cell response to stresses
treated with drug and a control vehicle. MS-275
such as DNA damage by inducing apoptosis.5
is a histone deacetylase inhibitor and known
In retinoblastoma, because the p53 gene is
anti-tumor compound previously proven to
intact yet suppressed, it is a prime target for
suppress retinoblastoma cell growth in vitro. The
up-regulation to promote apoptosis and stop
rats were treated with either MS-275 or vehicle
clonal expansion in tumors. The purpose of
every other day for 12 days and were imaged
this research is to develop more effective, less
using a Luciferin assay every other day. Our
toxic novel chemotherapeutic treatments using
results indicate statistically significant inhibition
small molecules that up-regulate p53 to induce
of tumor growth with MS-275 treatment when
apoptosis in p53-suppressed retinoblastoma cells.
P53 SIGNALING
Continued on p. 24
By identifying compounds in a National Cancer
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children receiving carboplatin for retinoblastoma.
European Journal of Cancer, 2006; 42:492–500.
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compared to control animals (Figure 1). At the
end of the treatment period, MS-275 treated
animals had 62 percent tumor growth inhibition
when compared to vehicle-only control animals
(p = 0.038).
Through the analysis of 140,000 compounds
in the NCI library for small molecules that are
good candidates for in vitro and ocular xenograft
model experimentation, we plan to identify novel
antitumor chemotherapies for the treatment of
retinoblastoma.
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Several studies have documented an association
among the patient population. Two patients had
between congenital heart disease and scoliosis
congenital heart disease, two had congenital
in children.1-4 More recent research has shown
cardiomyopathy and one had Marfan syndrome.
that children undergoing any type of solid
Hospital charts were reviewed to obtain clinical
organ transplantation are placed at increased
information regarding the heart transplantation,
risk for developing a potentially limiting
the spinal procedure and the patient’s status
5
spinal curvature. Among all solid organ
(both cardiac and spinal) at the time of
transplantations,
heart
… spinal deformity surgery can be successfully performed
transplantation
has been reported
in children and adolescents who have undergone heart
to be a major
transplantation.
risk factor for the
development of
spinal deformity.5 Armed with this knowledge,
scoliosis correction. Diagnostic test results,
the pediatric orthopaedic research team at
including preoperative cardiac catheterizations,
Morgan Stanley Children’s Hospital of New
echocardiograms and preoperative Cobb
York-Presbyterian Hospital reviewed the cases
angles, were obtained from the surgeon’s notes.
of patients undergoing scoliosis correction after
Intraoperative and follow-up information
orthotopic heart transplantation to establish any
also was reviewed. Three different procedures
necessary changes in their perioperative care to
were used to correct the scoliosis in the heart
ensure good surgical results.
transplant patients. Four patients underwent
This study was a retrospective case series
a posterior spinal fusion and instrumentation,
report of six heart transplant recipients with a
one patient underwent a posterior segmental
diagnosis of scoliosis, requiring corrective spinal
instrumentation without fusion (growing rods),
surgery between 1995 and 2007. The causative
factor necessitating heart transplantation varied
SPINAL DEFORMITIES
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and the last patient received an anterior release
and posterior fusion with instrumentation.
The average age at time of heart
transplantation was 7.8 ± 4.5 years. The children
then underwent surgical correction for their
scoliosis at a mean age of 13.3 ± 5.6 years.
Average length of follow up after the scoliosis
surgery was 21.5 ± 14.7 months. Two of the
patients in the cohort died as a result of their
cardiac condition. Three patients had
complications following the scoliosis
procedure. These complications included
a fractured single rod construct in one
patient, device migration after initial
surgery in another patient and one
instance of wound infection. None of
the complications resulted in adverse
sequelae. Appropriate curve correction
and control was achieved for all six
patients. The mean preoperative major
curve was 70.2°. At the time of last
follow up, the spinal curvature had
corrected to a mean curve of 22.6°
(p<0.10).
This case report demonstrates
how spinal deformity surgery can be
successfully performed in children
and adolescents who have undergone
heart transplantation. Especially
with immunosuppressive therapy
and numerous comorbid conditions,
these patients represent an especially
challenging cohort. Adequate
surgical correction without serious
adverse conditions, therefore, is
best accomplished with meticulous
preoperative planning and extensive
multidisciplinary cooperation both
intraoperatively and postoperatively.
Despite the risks and challenges,
correction of spinal deformity in
pediatric heart transplant patients can
significantly improve quality of life.

REFERENCES:
1.

BEALS RK, KENNEY KH, LEES MH. Congenital heart

disease and idiopathic scoliosis. Clin
Orthop Relat Res, 1972; 89:112-6.
2.

FARLEY FA, PHILLIPS WA, HERZENBERG JE, ROSENTHAL
A, HENSINGER RN. Natural history of scoliosis

Fusion • 2008

in congenital heart disease. J Pediatr Orthop, 1991;
11:42–7.

Continued from p. 24
3.

KAWAKAMI N, MIMATSU K, DEGUCHI M, KATO F, MAKI S.

Scoliosis and congenital heart disease. Spine, 1995;
20:1252–6.
4.

RECKLES LN, PETERSON HA, WEIDMAN WH, BIANCO AJ. The

association of scoliosis and congenital heart defects.
J Bone Joint Surg Am, 1975; 57:449–55.
5. HELENIUS I, ET AL. Scoliosis after solid organ
transplantation in children and adolescents. Am J
Transplant, 2006; 6:324–30.

FIGURE 1:
POSTOPERATIVE
LATERAL X-RAY OF
A STUDY PATIENT.

Note the posterior spinal
instrumentation inserted during
the scoliosis surgery as well
as the anterior staples used to
fuse the sternum following the
heart transplantation.
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performed as an outpatient procedure using fluoThis project aimed to assess the long-term
prognosis for patients who presented with femoroscopy for instrument placement. The proceroacetabular impingement (FAI) and underwent
dure has been slower to evolve than arthroscopy
subsequent hip arthroscopy. FAI occurs when
of other joints because the hip is much deeper
the femoral head does not have its full range of
in the body. Furthermore, because the hip is a
“ball‑and‑socket” joint, it is necessary to employ
motion within the pelvic acetabulum. FAI is
traction to expose the joint enough to fit the surincreasingly recognized as a cause of osteoarthritis
gical instruments inside
in the hip through detewithout causing further
rioration of the labrum
tissue damage. The basic
and articular surface.
principle of surgical
Impingement itself is the
treatment of FAI is to
premature and improper
restore sphericity to the
collision between the
femoral head, thereby
head and/or neck of
relieving the impingethe femur and the
ment. The surgery also
acetabulum. This causes
aims to address the
a painful and decreased
pathological changes in
range of hip joint
the labrum and articular
motion. FAI commonly
cartilage.1
presents as “cam-type”
Studies have shown
impingement, a result
that
the vast majority of
of excess bone forming
FIGURE 1: BALL‑AND‑SOCKET JOINT. A) Normal
around the head and/
hip; B) Cam impingement; C) Pincer impingement; D) Combination hip arthroscopy patients
return to sports and
or neck of the femur;
of cam and pincer impingement.
other physical activities
“pincer-type” impingeat their peak level of
ment, an overgrowth of
performance prior to the onset of hip pain. The
the acetabular rim; or a resulting FAI where the
majority of patients clearly get better, but it is not
acetabulum is angled in such a way that abnormal
yet clear to what extent the procedure stops the
impact occurs between the femur and the rim of
1
course of arthritis. Patients who have underlying
the acetabulum.
skeletal deformities or degenerative condiWhen the excess bone present on the femoral
tions may not experience as much relief from
head and/or neck abuts the rim of the acetabthe procedure as would a patient with simple
ulum, the cartilage and labrum that line and
impingement.
cushion the acetabulum can be damaged. The
extra bone can appear on X-rays as a small protruREFERENCES:
sion. When the protrusion repeatedly rubs against
1. CLOHISY JC, MCCLURE JT. Treatment of anterior femoroacthe cartilage and labrum, such as in athletes who
etabular impingement with combined hip arthrosperform repeated leg flexion and extension, the
copy and limited anterior decompression. The Iowa
cartilage and labrum eventually may tear, causing
Orthopaedic Journal, 25:164–71.
pain. As more tissue tears, the femoral bone will
impact with pelvic bone resulting in arthritis.
2. ESPINOSA N, BECK M, ROTHENFLUH DA, GANZ R, LEUNIG M. TreatTears of the labrum can also fold into the joint
ment of femoro-acetabular impingement: preliminary
space, causing a further painful restriction of hip
results of labral refixation. Surgical technique. The
motion.2,3
Journal of Bone and Joint Surgery, 2006; 88:925–35.
Arthroscopy of the hip has become an
3. SHUGARS RA, MORE RC. Arthroscopic hip surgery. The
accepted surgical procedure with well-defined
Association of Perioperative Registered Nurses Journal,
indications and expected outcomes, primarily
2006; 82:975–98.
due to recent advances in surgical instrumentation and techniques.3 Hip arthroscopy is
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Novel “Non-Fusion” Technologies May Help
Patients with Spinal Stenosis
indications and contraindications for each
Technological advances, especially spanning
device. Of these patients, 22 percent were eligible
the last two decades, have greatly advanced the
to receive an interspinous spacer, 30 percent
field of spinal surgery. Many of these advances
focused on creating alternatives to spinal fusion.
were eligible to undergo facet replacement and
Historically, spinal fusion has been widely
34 percent were eligible to receive posterior
dynamic stabilization. Twenty-three percent of
used to treat degenerative pathologies in the
David Goodwin, MSII
patients were eligible to receive all three devices,
spine. However, eliminating vertebral motion
Advisor: Warren Yu, MD
The George Washington
while 65 percent were not eligible to receive
and placing greater stress on adjacent spinal
University, Washington, DC
any device. Reviewing 100 patients who had a
segments limits the effectiveness of these fusions.
lumbar surgery other than fusion, 25 percent of
As a result, new classes of non-fusion surgical
patients were eligible to receive an interspinous
devices have emerged, including interspinous
spacer, 26 percent were eligible to undergo facet
spacers, facet replacement systems and posterior
replacement and 27 percent were eligible to
dynamic stabilization systems. These devices
receive posterior dynamic stabilization. Twentyoffer innovative, as well as minimally invasive,
five percent of patients were eligible to receive all
approaches to spinal surgery. The interspinous
three devices and 73 percent were not eligible to
spacer, facet replacement system and posterior
receive any of the devices.
dynamic stabilization are each indicated to treat
Interspinous spacers, facet replacement and
spinal stenosis.1,2
posterior dynamic stabilization, therefore, stand
This retrospective study evaluated the
to impact 20–30 percent of lumbar surgeries.
percentage of patients who would be eligible
to receive one of these
As future research and technology expand the indications or eliminate
non-fusion devices.
Eligibility was defined
the contraindications for these devices, the number of patients eligible to
as matching at least one
indication but none of the
receive these devices may increase significantly.
contraindications for each
device. There have been no
As future research and technology expand the
published studies investigating the percentage of
indications or eliminate the contraindications for
patients who may potentially benefit from any of
these devices, the number of patients eligible to
these devices.
receive these devices may increase significantly.
Patients were divided in two groups, the first
We predict that these devices will have a
including patients who had a lumbar fusion
significant impact on spine surgery.
and the second consisting of patients who had
any other lumbar surgery. Indications and
REFERENCES:
contraindications in this study were adapted
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from IDE clinical trials for interspinous spacers,
with and without instrumentation. Spine, 1995;
facet replacement and posterior dynamic
20:143S–153S.
stabilization. We evaluated the inclusion/
2. ESSES S, HULER R. Indications for Lumbar fusion in the
exclusion criteria for multiple models in each
Adult. Clinical Orthopedics and Related Research,
category and selected the most stringent criteria.
1992; 279:87–100.
As a result, indications and contraindications
were based on the inclusion/exclusion criteria
for the IDE clinical trials of X Stop interspinous
spacer, Anatomic Facet Replacement System and
Stabilimax posterior dynamic stabilization.
Medical records of 100 patients who had
lumbar fusions were cross-referenced with
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Vertebral compression fractures are the most
common injuries resulting from osteoporosis,
with an estimated incidence of 700,000 per year
in the United States.1 Among persons over 65,
33 percent of women have sustained a vertebral
compression fracture, and this fracture rate is
three times higher in women than in men. These
fractures cause acute and chronic back pain,
disability and increased mortality risk.2 One
treatment option is percutaneous vertebroplasty
or injection of cement, typically polymethyl
methacrylate (PMMA) acrylic bone cement, into
the vertebral body. However, previous studies
have shown that injecting an excessive amount
of cement can increase the risk of both cement
leakage and secondary adjacent fractures.2 While
the primary purpose of the surgery is to eliminate
back pain, patients and practitioners expect other
benefits, including mechanical reinforcement
of the vertebra as well the prevention of adverse
effects.
The primary objective of this study was to
determine how bone mineral density (BMD)
affects mechanical stiffness and strength of the
vertebral body after vertebroplasty. A secondary
objective was to determine how the relationships between mechanical properties and BMD
vary with the amount of cement injected. The
clinical goal of this research was to help physicians understand how BMD can identify a dose
of cement that can restore mechanical properties
to the greatest extent possible for a specific patient
without increasing the risk of complications.

Bone mineral density of 13 vertebral columns
from adult Caucasian female cadavers was measured with a dual-energy X-ray absorptiometry
(DEXA) scanner. Vertebral bodies (n=126) were
assigned to five groups based on cement treatment: intact, untreated, 4 percent fill, 12 percent
fill and 24 percent fill. Non-intact specimens
were compressed asymmetrically to simulate a
wedge compression fracture before treatment
with PMMA cement. Strength and stiffness were
measured in axial compression.
The two most significant findings of the
study suggest that: (1) the improvements in
stiffness and strength resulting from vertebroplasty depend significantly on bone density, and
(2) only the highest cement dose in the study
(24 percent vertebral body fill, average of 7 mL)
had an appreciable effect on either mechanical
property. Regarding strength, only the 24 percent fill group improved strength over untreated
levels, and greater improvements in strength
were seen in patients with higher bone density.
Unlike stiffness, however, the strength of the 24
percent fill group not only improved relative to
the untreated group but was enhanced beyond
the intact levels. The greatest improvements
in stiffness would be expected in patients with
higher bone density (who are the least likely to
suffer a fracture or need vertebroplasty). Results
suggest that highly osteoporotic patients may
receive the least amount of improvement in
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Continued on p. 29

FIGURE 1: X-RAYS
VERIFYING CONSISTENT
VERTEBROPLASTY.

All cement was injected using a
transpedicular approach through
the left pedicle with the needle tip
in the anterior third of the vertebral
body near the axial midplane. (A)
L3 vertebra injected with 4 percent
volume of cement. (B) T12 vertebra
injected with 12 percent volume of
cement. (C) L2 vertebra injected with
24 percent volume of cement.
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mechanical properties from vertebroplasty. For
these patients, it may be advisable for clinicians
to limit their expectations of vertebroplasty to
pain relief but not mechanical benefit and to
select a cement volume that will minimize risks
of adverse events.
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Identifying the Correlation between Pseudo-bulbar
and Cognitive Impairment in Primary Lateral Sclerosis
Primary Lateral Sclerosis (PLS) and Amyotrophic
Lateral Sclerosis (ALS) both involve degeneration of neurons. In PLS, loss of corticospinal
tract Upper Motor Neurons (UMN) results in
stiffness and brisk reflexes. In ALS, there is loss
of UMN and Lower Motor Neurons (LMN);
as a result, one finds atrophy, fasciculation
and diminished reflexes in addition to UMN
findings.
Although Pringle et al have developed a classification scheme for PLS, there still remains a
question as to whether PLS and ALS are indeed
separate disease entities.1 A previous study found
that stiffness and spasticity are more commonly
seen at the initial presentation of PLS and that
wasting of the limb is rare, and concluded, “a
patient presenting with spasticity who does not
develop wasting within three years most likely
has PLS.”2
ALS patients often manifest cognitive
changes of frontal lobe executive dysfunction to
varying degrees, in some cases leading to frontotemporal dementia (FTD). These impairments
are most commonly seen in those ALS patients
with bulbar impairment. Schreiber et al found,
“there is a fronto-temporal pattern of cognitive
dysfunction in ALS expressing itself early in the
course of the disease and mainly with bulbar
forms.”3 Furthermore, Lomen-Hoerth found in
her study that half of patients showed executive
function deficits.4
To further elucidate whether there is a distinction between ALS and PLS, our study aimed
to determine if a correlation exists between
bulbar dysfunction and cognitive impairment
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in the PLS population. Fifteen PLS patients and
six age-matched, healthy volunteers participated
in the study. The full battery of bulbar function
measures were carried out on 14 of the patients
and two of the volunteers. This work up included
clinical examination measures for hyperreflexia
in addition to two speech measures: the rate of
speech and the Assessment of Intelligibility of
Dysarthric Speech test. The measures of the rate
of speech and clarity of enunciation declined in
parallel; as speech became slower it also became
more difficult to understand. Rate of speech
also reflected the presence of hyperreflexia; brisk
jaw jerks and gag reflex were associated with
slow rates of speech as well. The rate of speech
was thereafter used as the primary measure of
bulbar function for comparison with the Mattis
DRS-2 dementia score. The psychologist in our
group obtained the dementia scores for 14 of the
patients and six of the volunteers.
Preliminary analysis of the correlation
between rate of speech and scores on the Mattis
dementia scale does not suggest a correlation at
this time. Regression analysis with a straight line
fit was performed in an attempt to elucidate this
relationship. We concluded that the relationship
between cognitive function and bulbar dysfunction should be studied in a larger population of
patients with PLS and compared to patients with
ALS to better understand the common features
of these disorders. Furthermore, understanding
the underlying cortical pathology by imaging
measures of atrophy as well as pathologic studies
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in PLS may further help explain the disease process itself.
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Although thrombotic diseases are less prevalent
in children than in adults, complex pediatric
patients, such as those with congenital heart disease, remain at risk for clot formation. Few guidelines exist for treatment of pediatric patients,
leading pediatric practitioners to prescribe
drugs, such as clopidogrel, off-label based upon
extrapolation from adult experience and perceived
clinical need.
Evidence-based information on clopidogrel, a
thienopyridine derivative and potent antiplatelet,
is limited to adults at risk for, or with a history
of, ischemic stroke, acute coronary syndrome,
peripheral arterial disease or are at risk of death
from vascular disease.1 Several large, randomized
trials have evaluated the safety and efficacy of
clopidogrel in adults using pre-determined dosing
criteria, and generally found the drug to be safe
and efficacious.2,3,4
Published material supporting the safety and
efficacy of off-label use of clopidogrel in the pediatric population remains scarce. Several pediatric
studies of clopidogrel performed outside of the
United States are underpowered by small sample
sizes. Two such studies performed at the Hospital
for Sick Children in Toronto, Canada had cohorts
of only 15–17 patients. Overall, both studies
found clopidogrel to be well tolerated in children
with minimal adverse events, the majority due to
minor bleeding.5,6
We performed a study to provide descriptive
information about off-label treatment practice

with clopidogrel in a larger pediatric population. Patients (≤ 18 years) who were prescribed
clopidogrel between March 2002 and August
2005 were retrospectively identified at Children’s
Hospital, Boston, MA. Data from the time of
the first documented clopidogrel use to the most
recent follow-up were collected and adverse events
were classified according to seriousness and relationship to clopidogrel.
Among 90 patients, 53 percent were male, the
median age was 6.7 years and the median weight
was 23.6 kg at first clopidogrel use. Prescriptions
were mostly for cardiac indications (96 percent)
with the remainder for neurological indications (4 percent). Common cardiac indications
included history of thrombosis involving a conduit or shunt, abnormal vasculature with potential for low flow and device placement. Median
total dose was 1.3 mg/kg/day and duration of
therapy varied greatly (median 45 days, < one
day – four years). Minor bleeding occurred in
three patients, all on concomitant acetylsalicylic
acid (ASA). One patient experienced catastrophic
bleeding after a vessel tear during catheterization. Another patient with poor ventricular
function and a fenestrated Fontan (an operation
performed on children with complex congenital
heart defects) had baffle thrombosis and subsequent stroke while on clopidogrel and ASA.
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In conclusion, our study demonstrated that
clopidogrel prescribed for children of all ages
was well tolerated. Most prescriptions were for
thrombosis prevention in patients with cardiac
disease. Bruising and minor bleeding events
occurred rarely. While various trials demonstrate
the benefits of treatment with clopidogrel to prevent thrombotic events in adults, a need remains
for further clinical trials examining the safety and
efficacy of clopidogrel in children.2,3,4 A qualitative prospective study would provide additional
information about the burden of drug use on
families, and could capture additional information about dosing, safety and efficacy that can
improve the application of this drug in children.
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Development of Class I HLA Typing Assay for HIV
Clinical Trials in East Africa
Highly polymorphic human leukocyte antigen
(HLA) class I and II genes are important host
genetic factors whose encoded molecules form
intracellular complexes with pathogen-derived
peptides and migrate to surfaces of infected cells
and mediate adaptive immune responses. This
process is fundamental to HIV infection and
AIDS progression. While many relationships
between HLA genotypes and HIV/AIDS are
well established, scientists emphasize the need
to study the influence of HLA alleles on the
efficacy of HIV drugs.1,2,3 This need is apparent
in the development of a global HIV vaccine that
targets the diverse populations of Sub-Saharan
Africa, where an estimated 25 million people are
infected with HIV.4
These HIV vaccine clinical trial participants
are ideal candidates for studying HLA
genotypes. Subsequent identification of these
genotypes can in turn be used to interpret
drug efficacy in participants.1,5 “HLA typing”
describes methods used to identify HLA alleles
based on HLA gene sequences. Techniques
usually involve conventional polymerase
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chain reactions (PCR) which incorporate
sequence-specific primers (SSP), sequence
specific oligonucleotide probes (SSOP/SSO) or
sequence-based typing (SBT).6 Real time PCR
uses primer-probe combinations to distinguish
HLA alleles based on fluorescence emissions
and melting curve profiles, which are cheaper
than SBT and do not require loading agarose
gels which are prone to contamination. Many
real-time PCR systems also use 384-well reaction
plates, which produce large amounts of data in a
short period of time. Such advantages have made
it a popular method of HLA typing.7
I was part of a team developing an SSPreal time PCR assay for HLA class I typing to
support ongoing HIV vaccine clinical trials in
East Africa. During my time there, we developed
an assay capable of distinguishing among 14
alleles of the HLA-A locus of HLA class I known
to be predominant in 80–90 percent of East
African populations. The completed system,
which also will type the remaining HLA-B and

HLA TYPING

Olalesi Osunsade, MSI,
Advisors: Francine McCutchan,
PhD; and Gustavo Kijak,
PharmD, PhD, U.S. Military
HIV Research Program, Henry
M. Jackson Foundation for
the Advancement of Military
Medicine, Rockville, MD

Continued on p. 32

31

HLA TYPING

Continued from p. 31

HLA-C loci of HLA class I, will perform HLA
class I typing for four individuals in less than
two hours at a third the cost of SBT. Through
such efficiency, our assay also can be performed
in East African clinical trial field labs where
other laboratory tests are performed at low costs.
Besides studying the efficacy of drugs in these
settings, HLA genotyping data generated by our
assay can be combined with HIV sequencing
and epidemiological data from patients —
using bioinformatics tools — to study the
emerging selective pressures created by the AIDS
epidemic.8 Such premises were behind recently
demonstrated “HLA footprints,” which show
how HIV viruses mutate and escape immunity
in response to particular HLA types within a
population.9 This is just another suggestion for
how large-scale HLA genotyping data can be
used effectively.
Overall, through its ability to support the
large-scale and cost-effective HLA genotyping
needed for studying the efficacy of HIV vaccine
candidates in East African clinical trials, this
assay could be an important component in the
design of a global HIV vaccine.
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Gastric Stimulation for Vomiting, Nausea and Related Symptoms
Associated with Gastroparesis Using Enterra™ System
Gastroparesis is a stomach disorder characterized by delayed gastric emptying. Patients with
gastroparesis suffer from a number of gastrointestinal (GI) symptoms, including bloating, nausea,
vomiting, early satiety, postprandial fullness,
epigastric pain and heartburn. Gastroparesis
has become an increasingly common medical
condition among the United States population,
affecting more than 1.5 million people. No cure
for this disorder currently exists.
Non-operative therapies for patients with
gastroparesis include diet modification, drug
therapy (including Prokinetics and Anti-emetics)
and nutritional feeding via gastric or jejunal
feeding tubes. However, these approaches can
negatively affect the patient’s quality of life.
Surgical procedures include gastrectomy, pyloroplasty and gastrojejunostomy. However, these
procedures have provided limited success and are
prone to complications.
The George Washington University Medical
Center is one of 10 clinical sites in the U.S. participating in a novel treatment study for patients
with gastroparesis. Currently, 50 patients are
enrolled in the study, with plans to enroll more
patients in the future. This clinical trial is a
double-blinded, randomized study to evaluate
the safety and effectiveness of gastric stimulation on the frequency of nausea and vomiting
in patients with gastroparesis. The procedure
involves a surgical implant of an Enterra™ electrical stimulator, provided by Medtronic, Inc.,
onto the body of the stomach. Interim results of
the clinical trial, organized by Medtronic, show
that gastric stimulation reduces symptoms of
nausea and vomiting in patients for whom drug
therapy was unsuccessful. The goal of this study
is to induce a sustained reduction in the often
debilitating symptoms of this disease.
Patients were asked to fill out a monthly
diary of their symptoms prior to surgery to assess
their baseline frequency of nausea and vomiting,
early satiety, bloating, postprandial fullness,
epigastric pain, epigastric burning, chest pain
and chest burning. Several study-related tests
are performed to determine if the patient qualifies for the study. An implant is placed inside
the abdomen onto the body of the stomach and
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the electrical stimulation begins at the time of
surgery. After six weeks, patients are randomized
to either the “On” or “Off” position for three
months, then set to the opposite group for three
additional months. Patients are required to attend
scheduled follow-up appointments at three, six,
nine and 12 months post-implantation and annually thereafter until the study is closed. At each
follow-up appointment, subjects are assessed for
symptom severity, frequency, complications and
adverse events, health status, quality of life and
normal daily activities. The following symptoms
are assessed using a Likert scale of zero (absent)
to four (extremely severe): vomiting, nausea, early
satiety, bloating, postprandial fullness, epigastric pain, epigastric burning, chest pain, chest
burning and other symptoms.
The results from baseline to 12 months noted
a decrease in the frequency of vomiting, nausea,
early satiety, bloating, postprandial fullness, epigastric pain, epigastric burning, chest pain, chest
burning and other symptoms. Secondly, there was
a significant decrease in vomiting at each follow
up appointment: three, six, nine and 12 months.
Lastly, there was a significant decrease in the total
severity scores and frequency scores at each three
month interval up to 12 months.
This study demonstrated that Enterra™
gastric stimulation is an effective and safe treatment option for the reduction of the severity
and frequency of symptoms associated with
gastroparesis. This treatment has improved the
quality of life for many people and has allowed
them to carry out a normal lifestyle and feel in
control of their symptoms. Results of this study
will be used to support a pre-market approval
application (PMA) to the U.S. Food and Drug
Administration.

Ricky Singh Harika, MSII
Advisors: Fredrick Brody, MD;
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Department of Surgery,
Washington, DC

REFERENCES:
1. MEDTRONIC. Gastroparesis Fact Sheet. 2007; Retrieved
July 14, 2007 from http://wwwp.medtronic.com/Newsroom/LinkedItemDetails.do?itemId=1101836121811&i
temType=fact_sheet&lang=en_US.
2. FOX J, FOXX-ORENSTEIN A. Gastroparesis. 2006; Retrieved
July 14, 2007 from http://www.gi.org/patients/
gihealth/gastroparesis.asp
3. MEDTRONIC. Enterra™ Therapy: Gastric Electrical Stimulation (GES). 2007; Retrieved July 14, 2007 from
http://www.medtronic.com/neuro/enterra/.

33

Breast-Specific Gamma Imaging as an Adjunct Modality for the
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Mammography has remained the modality
noted and compared to the laterality and location
of choice for breast cancer screening with a
of the biopsy proven invasive cancer. The clinical
1-4
sensitivity of 78-85 percent. However, this
report in the patient’s record was used for BSGI
percentage declines significantly for women
interpretation and cases were not reinterpreted for
with dense breasts and sub-centimeter cancers.
the study.
Limitations such as these have resulted in the
Out of the 149 invasive cancers identified, 146
development of adjunct imaging modalities to
were recognized with BSGI, totaling a sensitivity
improve breast cancer detection.
of 98 percent for the BSGI detection of invasive
One such method involves nuclear medicine
breast cancers. There were three cancers unidentitechniques, in which physiological properties
fied by BSGI, each being of grade 1 histology and
of tumors are utilized to effectively make a
sub-centimeter lesion size. One explanation for
diagnosis. Most common among these is the
the inability of BSGI to find these three pathouse of 99mTc-Sestamibi with a general purpose
logically proven invasive cancers may be due to
gamma camera. Although
the posterior and otherwise
this modality has improved
FIGURE 1: BREAST SPECIFIC difficult to image area of
breast cancer detection by
the breast. In the case of
GAMMA IMAGING. Patient
a large margin, it has been
one patient, the small size
with a multifocal infiltrating ductal
found to be inadequate in
carcinoma of the left breast seen
of the breast along with
the discovery of non-palpable
as separate areas of increased
a posterior location may
lesions and those less than
radiotracer uptake in the craniocaudal be the cause for the nonone centimeter in size
view.
visualization of the lesion.
due to intrinsic resolution
Despite these limitations,
limitations.5–8
BSGI was still able to
To resolve these difficulties, a small fieldidentify 40 percent (2/5) sub-centimeter, grade 1
of-view camera was developed that allows
tumors. Moreover, our study showed four out of
high-resolution detection of breast lesions.9 This
149 infiltrating ductal carcinoma cases that were
technique, Breast Specific Gamma Imaging
pathologically categorized as multifocal. BSGI
(BSGI), is a substantial improvement over the
was able to correctly identify the multifocality in
general purpose gamma camera model. The
all instances.
design of BSGI allows one to reliably image subOur results demonstrate that BSGI is a highly
centimeter lesions due to its improved resolution
sensitive method of diagnosing invasive breast
and shape which is optimized for breast imaging.
cancer. This study, using the largest sample size of
Furthermore, images acquired from the device are
invasive cancers studied with BSGI to date, along
in projections correlated to the medial-lateral and
with data in the literature, also suggests that
craniocaudal views of traditional mammography,
BSGI is a reliable adjunct imaging modality.
allowing images to be interpreted in a straightforward manner. Until now, there have been limited
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Religious Experience in Epilepsy
The ancient association between epilepsy and
having a concurrent religious/spiritual experience
has persisted through the ages and remains
to the present day. People with epilepsy have
been reported to have heightened religious
experiences and spiritual orientations from
a clinical perspective. In particular, people
with temporal lobe epilepsy (TLE) have been
described as intensely religious, preoccupied with
the study and practice of spirituality/religion
and frequently report intense spiritual/religious
experiences. Waxman and Geschwind (1975)
proposed an Interictal TLE Personality citing
“hyperreligosity,” an excessive preoccupation
with religion/spirituality, as a distinct behavioral
trait among its probable characteristics.1
The TLE Interictal Personality was further
investigated by Bear and Fedio (1977) using
a structured personality inventory and hyperreligiousness was among the set of 18 personality
traits consistently observed in TLE patients.2
The proposition of an interictal TLE Personality
has been controversial and our attempt to verify
this syndrome, in addition to other studies, have
been met with mixed results.
Our study evaluated the religiousness/
spirituality of TLE patients as compared with
patients with primary generalized epilepsy
and other types of focal epilepsy to determine
whether TLE patients are more religious/spiritual
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than other epileptics. We hypothesized that TLE
predisposes individuals to a heightened sense of
religiousness/spirituality, also associated with
neuroplastic changes, the net effect of which is to
enhance sensory activation of the limbic system.
A systematic survey of religious experience in
epilepsy, with a focus on TLE, was conducted
with a more comprehensive questionnaire
on spirituality/religion than previously
administered.
Data for this study was collected from
adults admitted to the New York University
Comprehensive Epilepsy Center inpatient
video-EEG monitoring unit between April 16,
2001 and Sept. 16, 2002. The study population
consisted of 151 patients with various types
of epilepsy. The Brief Multi-Dimensional
Measure of Religion/Spirituality for use in
Health Research (BMMRS) was used to assess
individual religiousness/spirituality.3 The
BMMRS is a 39-item questionnaire developed
by the Fetzer Institute in association with
the National Institute on Aging (1999) that
examines 11 different domains of religiousness/
spirituality which have been identified as related
to physical and mental health.
We found TLE patients are no more
religious/spiritual than other epilepsy patients

RELIGION AND EPILEPSY

Shivani M. Bhatt, MSII,
Research Track
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Department of Neurology, NYU
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FIGURE 1: BMMRS
DOMAIN SCORES
REPRESENTED
BY OUR STUDY
POPULATION
(TLE SUBJECTS)
VS. THE GENERAL
POPULATION (GSS
SAMPLE). Scores are

scaled from 0-100 with higher
scores indicating experiences
with a greater degree of
religiousness/spirituality.
*Significant Differences (p
value < .05) in the BMMRS
mean scores of TLE subjects vs.
the general population (GSS
Sample) were found in nine out
of the 11 BMMRS domains:
Daily Spiritual Experiences
(p < .0001); Religious/
Spiritual Values and Beliefs
(p < .0001); Forgiveness
(p < .0001); Private Religious/
Spiritual Practices (p < .0001);
Positive Religious/Spiritual
Coping (p = .0010); Positive
Religious/Spiritual Support
(p < .0001); Organizational
Religiousness (p = .0017);
Negative Religious/Spiritual
Support (p = .0430); Overall
Self-Ranking (p < .0001).
There were no significant
differences in Religious/Spiritual
History and Negative Religious/
Spiritual Coping domains.

36

RELIGION AND EPILEPSY Continued from p. 35

REFERENCES:
1) GESCHWIND N, WAXMAN SG. The interictal behavior

and report fewer religious conversion experiences.
Upon comparison of the study population with
the BMMRS normative population distribution
data from the 1998 General Social Survey, we
found epilepsy patients as a whole are more
religious/spiritual than the general population.4
Our findings refute the purported
“hyperreligiosity” associated with TLE. No
direct causal relationship can be established
between seizure discharges in the temporal lobe
and deepened religiousness/spirituality. The
religious/spiritual preoccupation and intense
religious conversion experiences proposed as
part of the constellation of TLE personality
traits is not supported by our data. Heightened
religiousness/spirituality may be a trait common
among all epileptics, regardless of epilepsy type
and seizure origin.

syndrome of temporal lobe epilepsy. Archives of
General Psychiatry, 1975; 32: 1580–86.
2) BEAR DM, FEDIO P. Quantitative analysis of interictal

behavior in temporal lobe epilepsy. Archives of
Neurology, 1977; 8:454–67.
3) FETZER INSTITUTE/NATIONAL INSTITUTE ON AGING WORKING GROUP.

Multidimensional Measurement of Religiousness/
Spirituality for Use in Health Research: a report
of the Fetzer Institute/National Institute on Aging
Work Group, 1999; Kalamazoo, MI: John E. Fetzer
Institute.
4) DAVIS JA, ET AL. General Social Survey. The National

Data Program for Social Sciences, 1998; National
Opinion Research Center, University of Chicago.

Fusion • 2008

A Geometrical Forefoot Model: Relationship to Foot Function
In collaboration with the Motion Analysis
where P is the pressure, F is the focus and D
Laboratory of Leon Root, MD, biomechanical
is the distance from the center to a vertex. We
foot function was studied using a geometrical
hypothesized that feet with normal rectus alignforefoot model designed to assess and treat pedal
ment and function had a hyperbolic conic curve
pathology. Malleolar valgus index (MVI) and
describing their MTPJ relationships with an
center of pressure excursion index (CPEI) were
eccentricity greater than one.4,5
developed to measure static and dynamic foot
Barefoot plantar pressures were measured
function.1 Many sophisticated and complex foot
during one’s comfortable walking speed with
models have been created, however, none have
the Novel emed X system. The plantar loading
been used for clinical decision making.2,3 A simparameters (peak pressure, peak force, pressureplified mathematical approach was developed by
time integral) were measured in each anatomical
Demp to model metatarsal length patterns from
region of the foot (hallux, first–fifth MTPJs,
dorsoplantar X-rays by unique conic curves and
medial arch, lateral arch, medial heel and lateral
their eccenheel) using a masking algorithm. In Figure 2, the
tricities.4,5 Our
maximum pressure throughout the stance phase
FIGURE 1 of a healthy asymptomatic person (right) and a
study explores
the association
person with diabetes and HV (left) is illustrated.
between these
The areas of high pressure are indicated by the
model paramarrows. Note that
eters and the
the subject with
biomechanical
diabetes and HV has
foot function
higher plantar presin healthy
sures and a reduced
asymptomatic
CPEI indicative of
individuals.
overpronation as
The Demp
compared with the
forefoot model
healthy individual.
(Figure 1)
Using our simplified
constructs a conic curve through the metageometric forefoot
tarsophalangeal joint (MTPJ) centers. Five
model, conservaMTPJ x,y coordinates are used to solve the
tive or surgical
FIGURE 2
equation for a unique conic curve:
treatments may be
modified
to
optimally
convert
a pathological foot
AX2 + BX + CXY + DY + EY2 = 0
to a healthy asymptomatic foot with improved
where A, B, C, D and E are the resulting
biomechanical function.
five coefficients. In this study, medial and lateral
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FIGURE 1: CONIC
CURVE MODEL.
FIGURE 2:
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PRESSURES: healthy
(right), HV (left).
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public health issues. . .
Barriers to Therapeutic Cancer Vaccine Development
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Therapeutic cancer vaccine development is
that inhibit T-cell responses and tumor escape
an exciting and rapidly evolving discipline of
mechanisms.7
biotechnology. However, it is undoubtedly burWhile scientific innovation remains the prindened by a variety of obstacles that need to be
cipal factor for determining success, a paradigm
addressed before success can be achieved.
shift in three regulatory factors could greatly
Therapeutic vaccines energize the body’s
facilitate the development process.
immune system to recognize and attack estabFirst, the current regulatory system is geared
lished tumors that are otherwise ignored by
to support single-agent drug approvals, yet
normal physiologic immune surveillance.1
combinations may be necessary. There is an
Prophylactic vaccines, on the other hand, are
increasing trend in therapeutic vaccine developadministered to healthy individuals and are
ment toward the use of multiple antigens and
designed to prevent infection from canceradjuvants. Attacking cancers from several angles
2
causing viruses.
may yield synergistic and clinically significant
As of August 2007, two prophylactic cancer
results.1
vaccines had been approved by the Food
Second, traditional efficacy endpoints, which
and Drug Administration (FDA). In 2000,
are based on quantitative tumor assessments,
ENGERIX-B was
approved to prevent
While a variety of tumor-associated antigens have been
primary liver cancer
as a result of chronic
identified and many immunotherapeutic strategies
hepatitis B infection.
have been tested, objectively defined clinical responses
In 2006, Gardasil was
approved to prevent
are rare.
infection from some of
the most common strains
of human papillomavirus that cause cervical
may not always adequately assess clinical benefit
cancer.2 Currently, the scope for cancer prophy(i.e., survival and quality of life). Tumor response
laxis is limited because few cancers are caused by
and patient response are not necessarily mutually
3
viruses.
inclusive.8 Thus, when a candidate vaccine meets
Therapeutic cancer vaccines, however, have
specified safety standards, various efficacy criteria
the potential to combat nearly any type of estabshould be considered to account for this potential
lished tumor. Yet, so far none have reached the
discrepancy.
market by earning FDA approval.4,5 This lack of
And third, current designs of clinical trials
success can be attributed to both scientific and
can be made more efficient and effective. The
regulatory barriers.
adaptive clinical trial approach, which employs
As a collection of altered self cells, tumors
Bayesian statistical methods, offers a scientificontain many of the same identification markers
cally rigorous alternative to the classic design.9
as normal cells of that tissue. That, in part,
This approach is suitable in studies as informamakes it difficult to convince the immune system
tion accrues during a trial, potentially allowing
to attack and eradicate tumors.6 While a variety
for smaller and more informative trials and
of tumor-associated antigens have been identified
enabling patients to receive better treatments.
and many immunotherapeutic strategies have
Furthermore, this approach better handles combeen tested, objectively defined clinical responses
bination therapies and multiple endpoints.10
are rare. The reasons for this include the inability
Implementing these changes may help
of current approaches to generate efficient
bring quicker approvals of safe and efficacious
T-cell responses, the presence of regulatory cells
VACCINE BARRIERS
Continued on p. 39

Fusion • 2008

VACCINE BARRIERS

Continued from p. 38

therapeutic cancer vaccines. That, in turn,
would encourage further innovation, leading to
improved treatments that can increase the duration and improve the quality of life.
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Increasing Awareness and Access to Emergency Contraception
Each year, approximately 750,000 to 850,000
adolescent women become pregnant in the
United States, and of these pregnancies, 74 to 95
percent are unintended or unwanted.1 Teenage
mothers are less likely to receive timely prenatal
care and are more likely to smoke during
pregnancy. Babies born to teenage mothers are
at increased risk of low birth weight, pre-term
birth, serious chronic illnesses or developmental
delays.2 Due in part to these significant
outcomes, understanding teen pregnancy and
assisting teens who wish to delay childbearing is
an issue of increasing public health and medical
importance.
Recent estimates suggest that approximately
46 percent of high school students and 80
percent of college students between 18 and 24
have had sex.3 The National Longitudinal Study
of Adolescent Health found that sexual activity
during adolescence is associated with inconsistent
or no use of contraception.4 Marginalized
youth, including youth of color, youth in foster
care, and low-income youth are more likely
to be confronted with financial, cultural and
institutional barriers to obtaining health care
which may contribute to their increased risk of
negative sexual outcomes.5 Developing health
programs to address teen pregnancy, especially
among high-risk populations, is a major
challenge requiring multi-level approaches.
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In 2006, the Harlem Health Promotion
Center (HHPC) began developing an
Emergency Contraception (EC) awareness
campaign to address the dire need for enhanced
contraception options amongst its high-risk
Black and Latino patient populations. To
date, there is a deficiency in culturally specific
and tailored intervention materials for this
population, and research indicates high rates of
teen pregnancy coupled with a lack of awareness
about EC.6 This project titled “EC as 1, 2, 3”
utilizes community-based participatory research
and social marketing techniques.
This model relied on a youth development
theory, and allowed youth to actively participate.
For the summer of 2006, a group of 10 Black
and Latino “youth experts” between the ages
of 15 and 20 were selected to participate. These
“experts” assisted with major tasks, including
incorporating the findings of formative research
with experiential knowledge. The participants
also worked with a Harlem-based filmmaker
and design students from Parsons New School
of Design. Additionally, as the Youth Advisory
Board Coordinator, I developed and coordinated
a comprehensive youth development curriculum
which included leadership and professional
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consistency in U.S. teenagers’ most recent sexual
relationships. Perspect Sex Reprod Health, 2004;
36:265–75.

Continued from p. 39
development, critical social analysis and media
training for the affiliated youth.
In May 2007, the project materials, which
included an educational DVD, brochure,
posters and Web site were launched for use with
the Center’s Mobile Health Team outreach to
high-risk youth and for use
in training and educational
sessions with medical, nursing,
and public health students and
clinical providers. The overall
project succeeded in producing
outstanding educational
materials for youths. As one
youth stated, “they were ready
to hear our voice and make it
an echo for change.”
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FIGURE 1: ADVERTISEMENT FOR “EC AS 1,2,3” CAMPAIGN
FOR EMERGENCY CONTRACEPTION.
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travel abroad. . .
Medical Relief Efforts in Jammu, India
Since India attained independence in 1947,
Jammu and Kashmir have been in a state of political and social turmoil due to tensions between
Hindus and Muslims. In 1990, tensions between
the groups peaked and many families had no
choice but to leave their homes and start fresh.
Seventeen years later, Kashmiris are still trying

FIGURE 1: MOTHER BATHING HER DAUGHTER
A MIGRANT CAMP IN JAMMU.
to get their lives back together and move on from
the terror they experienced.
In the summer of 2007, I traveled with support from the American Association of Physicians
of Indian Origin to Jammu, India. Under the
guidance of Dr. K.L. Chowdhury and his staff,
I worked inside migrant camps and at the Shirya
Bhatt Charitable Hospital in Jammu, India.
Diabetes has increased in prevalence within
the Kashmiri migrant community. About 25
percent of the adult population aged 18 and over
suffers from diabetes, and nearly 33 percent from
hypertension. The clinic suggested gathering
information on the management costs of diabetes in terms of medications and monitoring,
as well as the type of diet and the current blood
glucose levels. I prepared a survey and went to
the “quarters” of about 80 families and found
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that approximately 25 percent of their monthly
income went toward diabetes medications and
blood sugar testing for one person.
More valuable was learning about the lifestyle
changes each family made upon migration. Each
family was given a 10' by 15' room in which to
live in. A group of about 10 families was expected
to use one communal
bathroom, one water
pump and to live without
privacy from their neighbors. In that one room,
children would sleep,
play and study while
their parents cooked and
washed clothes.
Health care was also
a luxury. I remember
coming across a man
lying on the dirt floor in
front of his quarter with
a measured hemoglobin
of 3 and fever of 104
degrees. His children,
ages 10 and 8, stood
above his head, his wife
and mother pressing
AT A WATER PUMP IN
his feet and legs. His
elder brother stared at
him with fear in his eyes. His pale skin and weak,
unmoving body made me think he was going to
pass away before me. The nearest hospital was
20 miles away, and there was no ambulance to
take him, nor were the funds available to pay for
his care. A previous doctor had recommended a
blood transfusion, but there was no Type A blood
type match in his family.
As a medical student, I was unable to help. I
could not offer any physical comfort. Instead, he
gave something to me. He reaffirmed my reasons
for aspiring to become a physician: to provide
relief and support. I want to work in this type
of community: where resources are sparse, and
the need is great. Dr. Chowdhury and his staff
amazed me with their tireless efforts to aid this
community and demonstrated how effort and
passion can create positive change.

Cherie-Priya Dhar, MSII
Global Health Track
Advisor: K.L Chowdhury, MD
Shriya Bhat Mission Hospital,
Jammu, India
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A Place of Learning: The Mondaña Clinic, Ecuador

M. Matthew Neimat, MSI
Global Health Track
Advisor: Robert Morrow,
MD, MPH
Mondaña Clinic, Yachana
Foundation, Ecuador
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During the three-hour canoe ride to Mondaña,
these illnesses are being addressed and treated.
the sun pierces through the dense foliage of the
For example, because many of these communities
Ecuadorian rain forest as the canopy rises and
have no running or potable water, the Yachana
falls along the river’s shore. My goals while in
Foundation developed a cheap water filtration
this beautiful setting were to involve myself in
system to improve community sanitation
the community healthcare system and patient
and thereby reduced parasitic and bacterial
population through education, conversation
infections. To address insufficient health
and treatment. In the
education, I spent
quiet of the headwind,
time teaching and
I wondered what
interacting with the
challenges lay ahead.
students from the local
The Mondaña
Yachana High School.
Clinic was started in
I had the opportunity
1995 by The Yachana
to discuss health and
Foundation to address
hygiene and to design
the needs of a large,
and implement a first
medically underserved
responder and sexpopulation. The
education course.
Clinic, located along
The Yachana
the Upper Napo River
Foundation was
in the Ecuadorian
started to address
rain forest, now
the health care needs
serves local Mondaña
of the underserved
and 25 surrounding
communities along
communities, with
the Upper Napo
a patient population
River and has now
of more than 10,000.
broadened its focus
FIGURE 1: APPROXIMATE LOCATION OF THE
These communities
to include education,
MONDAÑA
CLINIC
IN
ECUADOR.
are spread over a wide
eco-tourism, rain forest
geographic area, many
conservation, micro
accessible only by canoe or long hikes, making
enterprise and micro lending. The Foundation is
access to health care difficult. Nonetheless, the
so deeply involved in the lives of the surrounding
clinical staff makes regular visits. I traveled on
communities that it has become an integral
such a visit and was privileged to share meals
part of health, education and preservation
with families where I learned about the local
of the Upper Napo River. This was a unique
history, culture and health. The Mondaña
opportunity for me to learn about and make
Clinic is the cornerstone of health care in the
an impact on the health care and education of
area, and visits are a critical part of the Clinic’s
a large, underserved community. I observed,
responsibilities. They represent the beginnings
firsthand, what one organization is doing to
of a growing effort to provide for marginalized
preserve one of the world’s richest biological
populations within remote regions of Ecuador.
resources and improve the lives of its inhabitants.
In the Clinic, the lack of modern diagnostic
It came as no surprise to me when I discovered
technology forces doctors to rely on signs and
that, in the indigenous Quichua language, the
symptoms to differentiate diagnoses and treat
word Yachana means, “a place of learning.”
patients. I was challenged to learn these practical
REFERENCES:
skills promptly. During my time in the rain
1. Foundation for Integrated Education and
forest, I saw a variety of illnesses, the most
Development: Community Healthcare in the
common of which were parasitic infections,
Amazon Rain Forest. Retrieved from http://www.
the common cold or gripe, and malnutrition.
funedesin.org/html/health-care.htm. Accessed Oct. 8,
I learned a great deal about the ways in which
2007.
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other abstracts. . .
Development of a Longitudinal Genetics Curriculum
Genetics is an ancient science. Yet, recently, with
the description of the DNA molecular structure
and the completion of the sequencing of the
human genome, much more information relevant
to the practice of medicine is being revealed. The
evolution of the field from a basic descriptive
science of Mendelian genetics, drosophila and
other organisms, to cancer biology, molecular
immunology, cardiovascular genomics and
pharmacogenomics has made the management
of curricula change in U.S. medical schools seem
slow and fragmented. The ensuing gap between
available information and knowledge of medical

test were administered to third-year students
during their OB/GYN clerkship. The curriculum
in genetics reinforced genetic concepts learned
in the first two years of medical school and
introduced their clinical application. The curriculum, administered through Blackboard®, was
case-based using an organ-system approach, and
introduced students to relevant online genetics
resources. Students were presented clinical
vignettes on genetic diseases and answered clinically relevant questions about these disorders.
The curriculum was designed with principles
of adult learning theory to emphasize skills in
self-directed learning. After comPre-curriculum medical student surveys indipleting the curriculum, students
took a post-test and their scores
cated deficient knowledge and comfort with
were compared to their pre-test
genetics. Ninty-seven percent of the students were scores. Students then completed
an exit survey. In the pilot study,
comfortable speaking with patients about family 17 students completed the needs
assessment, and pre- and post-test.
Twelve of 17 students showed
history, but 31 percent did not feel comfortable
improved scores, with a mean
discussing a diagnosis of a genetic disease.
increase of 11.5 percent. Five of 17
failed to demonstrate improvement,
students, residents and practitioners, poses a chalwith a mean decline of 4.5 percent.
lenge for teaching and the dissemination of this
Pre-curriculum medical student surveys
vital information.
indicated deficient knowledge and comfort with
Although most medical schools have develgenetics. Ninety-seven percent of the students
oped genetics courses for first- and second-year
were comfortable speaking with patients about
medical students, the integration of basic science
family history, but 31 percent did not feel comand clinical medicine has lagged. In addition,
fortable speaking about a diagnosis of a genetic
exposure to genetics in the early years of medical
disease. In the exit survey, students expressed the
school and having to recall and apply it in the
need for a more robust genetics education curclinical years is a difficult task for most students.
riculum beginning in the second year. They indiThis educational shortcoming calls for the implecated overall satisfaction with our experimental
mentation of a genetics curriculum for medical
curriculum, particularly the online resources, and
students in their clinical years. Addressing this
recommended its future use.
disparity in genetics education during the medThe addition of this curriculum into the curical school years can improve the knowledge base
rent
GW SMHS curriculum would make medical
of future clinicians in these regards.
genetics education more longitudinal, reinforce
In recognition of this educational deficit,
genetics concepts in a clinical setting, and assist
researchers at The George Washington University
students in developing self-directed learning skills
School of Medicine and Health Sciences (SMHS)
to be better equipped to find genetics information
designed a genetics curriculum for third-year
throughout their careers. The curriculum will
medical students. A needs assessment, and
be administered to 180 GW medical students
pre- and post-test about medical genetics was
between July 2007 and June 2008.
developed. As a pilot study, the survey and pre-
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